

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 OCT 04 Precision of EMBASE searching enhanced with new  
chemical name field  
NEWS 3 OCT 06 Increase your retrieval consistency with new formats or  
for Taiwanese application numbers in CA/CAPLUS.  
NEWS 4 OCT 21 CA/CAPLUS kind code changes for Chinese patents  
increase consistency, save time  
NEWS 5 OCT 22 New version of STN Viewer preserves custom  
highlighting of terms when patent documents are  
saved in .rtf format  
NEWS 6 OCT 28 INPADOCDB/INPAFAMDB: Enhancements to the US national  
patent classification.  
NEWS 7 NOV 03 New format for Korean patent application numbers in  
CA/CAPLUS increases consistency, saves time.  
NEWS 8 NOV 04 Selected STN databases scheduled for removal on  
December 31, 2010  
NEWS 9 NOV 18 PROUSDDR and SYNTHLINE Scheduled for Removal  
December 31, 2010 by Request of Prous Science  
NEWS 10 NOV 22 Higher System Limits Increase the Power of STN  
Substance-Based Searching  
NEWS 11 NOV 24 Search an additional 46,850 records with MEDLINE  
backfile extension to 1946  
NEWS 12 DEC 14 New PNK Field Allows More Precise Crossover among STN  
Patent Databases  
NEWS 13 DEC 18 ReaxysFile available on STN  
NEWS 14 DEC 21 CAS Learning Solutions -- a new online training experience  
NEWS 15 DEC 22 Value-Added Indexing Improves Access to World Traditional  
Medicine Patents in CAPLUS  
NEWS 16 JAN 24 The new and enhanced DPCI file on STN has been released  
NEWS 17 JAN 26 Improved Timeliness of CAS Indexing Adds Value to  
USPATFULL and USPAT2 Chemistry Patents  
NEWS 18 JAN 26 Updated MeSH vocabulary, new structured abstracts, and  
other enhancements improve searching in STN reload of  
MEDLINE  
NEWS 19 JAN 28 CABA will be updated weekly  
  
NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer

agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:56:40 ON 11 FEB 2011

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.23

0.23

FILE 'REGISTRY' ENTERED AT 09:57:22 ON 11 FEB 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2011 HIGHEST RN 1262583-27-6

DICTIONARY FILE UPDATES: 10 FEB 2011 HIGHEST RN 1262583-27-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10590845.str



chain nodes :

10 17

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16

chain bonds :

9-10 10-11  
 ring bonds :  
 1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15  
 15-16  
 exact/norm bonds :  
 1-7 2-9 7-8 8-9 9-10  
 exact bonds :  
 10-11  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16


Match level :  
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS  
 18:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:57:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1026 TO ITERATE

100.0% PROCESSED 1026 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 18599 TO 22441

PROJECTED ANSWERS: 173 TO 747

L2                    23 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 09:58:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -    20169 TO ITERATE

100.0% PROCESSED    20169 ITERATIONS

524 ANSWERS

SEARCH TIME: 00.00.01

L3                    524 SEA SSS FUL L1

=> s 13 and caplus/lc

73628895 CAPLUS/LC


L4                    446 L3 AND CAPLUS/LC

=> s 13 not 14

L5                    78 L3 NOT L4

=> d 15 78


L5 APPROX 79 OF 79 REGISTRY COPYRIGHT 2011 ACS on STM  
 M0 551092-10-6 REGISTRY  
 ED Entered STM: 09 Sep 2003  
 CH Proprietary,  
 N-[2-oxo-1,7-naphthyl-3-[(4-nitrophenyl)methyl]-2H-imidazo[4,3-b]pyridin-6-yl]-2,2-dimethyl- [CA INDEX NAME]  
 M0 C13 R23 R1 C3  
 SS Chemical library  
 Suppliers Asinex  
 LC STM Files: CHEMISTS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> d 13 70

LJ ANKWA 70 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 NH 064172-18-9 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CH 4-*apex* diacetamide, 1-methyl-N-[(2,5,7-trimethyl-3*H*-oxadiazol-4,5-  
 alpyridin-3-yl)methyl]phenyl]- (CA INDEX 10000)  
 MT C21 H21 N5  
 SA CA  
 LC STM Files: CA, CAPLOS, TOXCENTER, USPATFOLL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLOS (1907 TO DATE)

=> d 13 71-77




L3 ANSWER 71 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 RN 864172-17-8 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN 4-(2-piperidin-2-yl)-N-(4-((2,5,7-trimethyl-2H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)-  
 (CA INDEX NAME)  
 MF C22 H27 N5 O  
 SA CA  
 LC STM Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 72 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 RN 864172-16-7 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN 4-Piperidin-2-yl-N-(4-((2,5,7-trimethyl-2H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)-  
 (CA INDEX NAME)  
 MF C22 H27 N5  
 SA CA  
 LC STM Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 73 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 RN 864172-15-6 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN 4-Piperidin-2-yl-N-(4-((2-ethyl-5,7-dimethyl-2H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)-1-(1-methylethyl)-  
 (CA INDEX NAME)  
 MF C25 H27 N5  
 SA CA  
 LC STM Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 74 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 RN 864172-14-5 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN 2H-Pyran-4-yl-N-(4-((2-ethyl-5,7-dimethyl-2H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)tetrahydro-  
 (CA INDEX NAME)  
 MF C22 H25 N4 O  
 SA CA  
 LC STM Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

LJ ANWEX 75 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 EN 864172-13-4 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN 4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl-1-(1-tetrahydro-2H-pyran-4-yl)- [CA INDEX NAME]  
 MF C25 H29 N5 O  
 SA CA  
 LC STM Files: CA, CAPLOS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLOS (1907 TO DATE)


LJ ANWEX 76 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 EN 864172-12-3 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN 2H-Pyran-6-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- [CA INDEX NAME]  
 MF C25 H29 N4 O  
 SA CA  
 LC STM Files: CA, CAPLOS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLOS (1907 TO DATE)

LJ ANWEX 77 OF 524 REGISTRY COPYRIGHT 2011 ACS on STM  
 EN 864172-11-2 REGISTRY  
 ED Entered STM: 29 Sep 2005  
 CN Cyclohexanol, 4-[[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, trans- [CA INDEX NAME]  
 MF C24 H32 N4 O  
 SA CA  
 LC STM Files: CA, CAPLOS, TOXCENTER, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
 1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLOS (1907 TO DATE)

=> fil caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
223.44	223.67

FILE 'CAPLUS' ENTERED AT 09:59:45 ON 11 FEB 2011  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2011 VOL 154 ISS 8  
FILE LAST UPDATED: 10 Feb 2011 (20110210/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.


16 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM

ACCESSION NUMBER: 1994/1475555 CAPLUS  
DOCUMENT NUMBER: 133/12355  
TITLE: Preparation of imidazopyridine derivatives as GPR4  
receptor modulators for treating angioneurotic, pain,  
autoimmune and inflammatory diseases.  
INVENTOR(S): Tarasidis, Ioan Cornelius; Harrington, Edward Martin;  
Harpurberg, Rene; Lathmann, Rene; Miltz, Wolfgang;  
Weigand, Klaus  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 50pp.  
COUNTRY: USANCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090144202	AI	20090112	US 20090144202	20090215
AI 71804	AI	20100721	US 2009014046	20090222
US 20090144201	AI	20090103	MO 20090146311	20090225
US 20090144203	AI	20090103	US 20090144203	20090225
US 20090144204	AI	20090103	US 20090144204	20090225
US 20090144205	AI	20090103	US 20090144205	20090225
US 20090144206	AI	20090103	US 20090144206	20090225
US 20090144207	AI	20090103	US 20090144207	20090225
US 20090144208	AI	20090103	US 20090144208	20090225
US 20090144209	AI	20090103	US 20090144209	20090225
US 20090144210	AI	20090103	US 20090144210	20090225
US 20090144211	AI	20090103	US 20090144211	20090225
US 20090144212	AI	20090103	US 20090144212	20090225
US 20090144213	AI	20090103	US 20090144213	20090225
US 20090144214	AI	20090103	US 20090144214	20090225
US 20090144215	AI	20090103	US 20090144215	20090225
US 20090144216	AI	20090103	US 20090144216	20090225
US 20090144217	AI	20090103	US 20090144217	20090225
US 20090144218	AI	20090103	US 20090144218	20090225
US 20090144219	AI	20090103	US 20090144219	20090225
US 20090144220	AI	20090103	US 20090144220	20090225
US 20090144221	AI	20090103	US 20090144221	20090225
US 20090144222	AI	20090103	US 20090144222	20090225
US 20090144223	AI	20090103	US 20090144223	20090225
US 20090144224	AI	20090103	US 20090144224	20090225
US 20090144225	AI	20090103	US 20090144225	20090225
US 20090144226	AI	20090103	US 20090144226	20090225
US 20090144227	AI	20090103	US 20090144227	20090225
US 20090144228	AI	20090103	US 20090144228	20090225
US 20090144229	AI	20090103	US 20090144229	20090225
US 20090144230	AI	20090103	US 20090144230	20090225
US 20090144231	AI	20090103	US 20090144231	20090225
US 20090144232	AI	20090103	US 20090144232	20090225
US 20090144233	AI	20090103	US 20090144233	20090225
US 20090144234	AI	20090103	US 20090144234	20090225
US 20090144235	AI	20090103	US 20090144235	20090225
US 20090144236	AI	20090103	US 20090144236	20090225
US 20090144237	AI	20090103	US 20090144237	20090225
US 20090144238	AI	20090103	US 20090144238	20090225
US 20090144239	AI	20090103	US 20090144239	20090225
US 20090144240	AI	20090103	US 20090144240	20090225
US 20090144241	AI	20090103	US 20090144241	20090225
US 20090144242	AI	20090103	US 20090144242	20090225
US 20090144243	AI	20090103	US 20090144243	20090225
US 20090144244	AI	20090103	US 20090144244	20090225
US 20090144245	AI	20090103	US 20090144245	20090225
US 20090144246	AI	20090103	US 20090144246	20090225
US 20090144247	AI	20090103	US 20090144247	20090225
US 20090144248	AI	20090103	US 20090144248	20090225
US 20090144249	AI	20090103	US 20090144249	20090225
US 20090144250	AI	20090103	US 20090144250	20090225
US 20090144251	AI	20090103	US 20090144251	20090225
US 20090144252	AI	20090103	US 20090144252	20090225
US 20090144253	AI	20090103	US 20090144253	20090225
US 20090144254	AI	20090103	US 20090144	

OTHER SOURCE(S): MARPAT 152:12353  
GI


16 ANSWER 1 OF 29 CAS138 COPYRIGHT 2011 ACS on STM (Continued)  
CN 1-Piperidinepentanamide, N-[4-[(2-methyl-5,7-dimethyl-3H-imidazo[4,5-  
b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




```

NN  1197879-88-1  CASLUS
CN  1-Pyrrolidinepentanamide,
3-(dimethylamino)-N-[4-[(2-ethyl-5,7-dimethyl-3H-
imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)

```




JT 1197880-45-79  
 NL P2P2 (Prophetic); RCT (Reactant); SPN (Synthetic preparation); P2P2  
 (Preparation); RACT (Reactant or reagent)  
 [Preparation of novel indazopyridine deriva. as GPR4 receptor  
 modulators]  
 For treating angioneurotic, pain, autoimmune and inflammatory diseases;  
 MN 1197880-45-7 CARLOS  
 CN Pentanamide,  
 5-chloro-N-[4-(1,2-ethyl-5, 7-indazol-3-yl)-indazo[4, 5-b]pyridin-  
 3-yl]methyl]benzyl- (CA INDEX NAME)



17	137423-01-5P	KL: RCT (Reagent); GRN (Synthetic preparation); PRKP (Preparation); RAC7 (Reagent or reagent) (preparation of novel imidazopyridine derivs. as GPR4 receptor modulators for treating angiogenesis, pain, autoimmune and inflammatory diseases)
18	137423-01-3 CAPUS	
19	benzamide, 4-[1-(2-methyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CAS INDEX NAME)	

16 ANSWER 1 OF 29 CAPLOS COPYRIGHT 2011 ACS on STM |Continued




AB The title compds. 1 [R1 = alkyl optionally substituted by halo; R2, R3 = H, alkyl; XY = C-tripbond, C, C#C#C, C#C#C, C#C#C, N#C, O#C; S = CH2, (CH2)2, (CH2)4, C, a bond; R4 = R, alkyl and R5 = alkyl substituted by heteroaryl] or NR4R5 = heterocyclyl or heteroaryl], useful in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases, were

For example, a multi-step synthesis of 11, starting from 2-methyl-5,7-dimethyl-38-indoliz-4,9-bispyridine and 4-ethoxythiophene bromide, would be a good example of a reaction to be tested in this assay for human GPR4 activity. For example, 11 showed IC50 of 189 nM. Pharmacological comments: comprising the compound 1, alone or in combination with other therapeutic agents, were discussed.


11 1157073-86-3P 1157073-87-0P 1157073-88-1P  
R1: FMC (Pharmacological activity); SFH (Synthetic preparation); TBS (Therapeutic use); R10L (Biological study); PREP (Preparation); USES (Uses).

for treating angiogenesis, pain, autoimmune and inflammatory diseases)



END 1197879-87-0 CAPL28


16 ANSWER 1 OF 29 CAPLOS COPYRIGHT 2011 ACS on STN (Continued)



IN	927822-05-7	CAPL08
CH	Methanone, 4-[[4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-(4-methyl-1-piperazinyl)-, ethanedioic (1:7) (CA INDEX NAME)	

CM 2

CJRT 927822-00-2  
CJRT C29 840 886 0



282

CFM 144-62-7  
CMF C2 R2 O4



22 064171-06-4P 064172-38-3P  
 23 EL: PAC (Pharmacological activity); SPN (Synthetic preparation); TUD  
 24 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 25 (Uses)


```

11      (preventives and/or remedies for X-ray induced lung injury containing
CE34      gamma-ray inhibitor)

```

320	064171-66-4	CAPLUS	
C20	Benzotriazine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-N-[trans-4-[4-methyl-1-piperazinyl)methyl]cyclohexyl]-	(CA	
	INDEX NAME)		

#### Relative stereochemistry



```

JN1 864172-38-3 CAPLUS
CN1 Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-inidazo[4,5-b]pyridin-3-yl)methyl]-N-[cisa-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA
INDEX NAME)

```


Relative stereochemistry.

ACCESSION NUMBER: 2007:227735 CARLOS  
DOCUMENT NUMBER: 1462466792  
TITLE: Chelonic production inhibitor  
INVENTOR(S): Sakai, Mayumi; Minura, Kazumi; Sasaki, Ratsutochi  
PATENT ASSEMBLY(S): Myowa Hakko Kogyo Co., Ltd., Japan  
SOURCE: PCT Int. Appl., B9pp.  
COMBIN. PENDING  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACQ. NUM. COUNT: 1  
PATENT INFORMATION:

[illegible]


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 146:266782  
GT



AS Disclosed are a chemokine production inhibitor comprising a substance capable of inhibiting the function involved in signal transduction of GPR4 as an active ingredient; a chemokine production inhibitor comprising a retrograde

tricyclic compound represented by the formula I (R1 represents a (un)substituted heterocyclopropyl group, -NR5aR5b where R5a and R5b independently represent H, a (un)substituted lower alkyl group or the like; R2 represents a H or the like; R3 and R4 independently represent a H or the like;  $n = 0$  or 1; R represents -CH2CH2 or the like; and Y represents the like; Z represents the like; and R6 represents a H or the like; R7 and R8 independently represent H, a (un)substituted lower alkyl group or the like; and R9 represents H or the like), or a quaternary ammonium salt or pharmacologically acceptable salt thereof as an active ingredient; and other pharmaceutically acceptable salts thereof.



16 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
antibody which binds specified proteins. For example, a compd.  
2-({2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl}-8-  
methylpiperazin-1-ylmethyl)-10,11-dihydro[6,f]azepine difumarate  
prepd., and examd. for its GPR4 antagonistic effect and IL-8 prod.

17 Inhibitory effect in vitro.  
B46171-B3-SP B46171-B6-SP  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(chemokine production inhibitor comprising substances capable of inhibiting

```

GPR4 signal transduction)
P01 B64171-B1-5 CAPLOS
C01 Methanone, [4-methyl-1-piperazinyl][trans-4-[[4-[(2,5,7-trimethyl-3H-
indol-4,5-b)pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX
WWW)


```

Relative stereochemistry




RXN 064171-06-8 CAPLOS  
 CN Cyclohexanecarboxamide, N-[2-[1-pyrrolidinyl)ethyl]-4-[4-[(2,5,7-trimethyl-7H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino-, trans-  
 (CA  
 INDEX NAME)


### Relative stereochemistry



IT 064172-71-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
[chenokline production inhibitor comprising substances capable of  
inhibiting



JT 044172-28-1P  
 K1: SYN (Synthetic preparation); TMS (Therapeutic use); B10L (Biological study); P123 (Preparation); U055 (Uses)  
 (chemokine production inhibitor comprising substances capable of inhibiting G294 signal transduction)  
 JT 044172-28-1L CAPLOS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)  
 Relative stereochemistry



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

16	ANIMEX 5 OF 21	CAPLUS	COPYRIGHT 2011 ACS on ETRI
	ACCESSION NUMBER:	2006:1224882	CAPLUS
	DOCUMENT NUMBER:	146178405	
	TITLE:	Identification of Previously Unrecognized Antiestrogenic Chemicals Using a Novel Virtual Screening Approach	
	AUTHOR(S):	Wang, Chang Y.; Ai, N.; Arora, Sonia; Krenlich, Erin; Nagaraja, Karthigaeyan; Zaichik, Randy; Young,	
	Douglas	Welsh, William J.	
	CORPORATE SOURCE:	Department of Pharmacology, University of Medicine	
	and	Dentistry of New Jersey-Robert Wood Johnson Medical School (UNGL-EMMNS), Piscataway, NJ, 08854, USA	

PROJECT:	Chemical Research in Toxicology (12066, 1912), 199-1603
NUMBERS:	COSPAR: CITEFY ICSEI: 0699-228R
LANGUAGES:	American Chemical Society
DOCUMENT TYPE:	English
ABSTRACT:	The physical roles of estrogen in sexual differentiation and development, and the role of estrogen in carcinogenesis, and bone health are complex and diverse. Numerous natural and synthetic chemical compounds, commonly known as endocrine disrupting chemicals (EDCs), have been shown to alter the physiological effects of estrogen in humans and wildlife. As such, these EDCs may be considered endocrine disruptors. EDCs have been shown to alter the physiological effects of estrogen in humans and wildlife. As such, these EDCs may be considered endocrine disrupting chemicals (EDCs).
OTHER:	undisputed and even undesirable effects. Large-scale in vitro and in vivo testing of the effects of EDCs on reproductive and endocrine systems demand a proactive investment of time, labor, and money and would require a comprehensive understanding of the mechanisms of action of EDCs.
ANALYSIS:	testing on an unprecedented scale. Approaches in silico are increasingly recognized as playing a vital role in screening and prioritizing chemicals for testing.

nated limited resources available for expl. testing. Here, we evaluate a multi-step procedure that is suitable for *in silico* (virtual) screening of large chemical databases to identify compds. exhibiting estrogenic activity. This procedure is based on the use of a number of simple, computationally fast that rapidly compare mols. on the basis of similarity in shape, polarity, and other 3D-relevant properties. Using a hydrophobicity and polarity scale, we have been able to identify 1000 compds. employed this scheme to search a sample database of approx. 300,000 comd. and to obtain a separate list of 1000 compds. that were most similar to the identified estrogenic compounds.

Subsequently, as per our protocol, a bioassay (estrogenic bioassay) confirmed two as putative unknown estrogenic antagonists. Subsequent radioligand binding assays confirmed that two of these three compounds, 1 and 2, were estrogenic antagonists. The third compound, 3, was found to be an estrogenic agonist. These results are consistent with the findings of studies of these ligands docked inside the binding pocket of estrogen receptor (ER) and the results of a recent study of the effects of these compounds that corroborate their expl. findings. The present study demonstrates the utility of our computational scheme for this and related applications such as, e.g., compound discovery, and the use of simple, computationally


in drug discovery, predictive toxicol., and virtual screening.

IT 921198-76-7  
RL: RSU (Biological study, unclassified); BIOL (Biological study)  
(identification of previously unrecognized antiestrogenic chems. using  
a novel virtual screening approach)

FN 921198-76-7 CAPLUS

CN 38-Imidazo[4,5-b]pyridin-5-amine, 2-butyl-6-methyl-2-[4-

16 ANSWER 5 OF 29 CASUS COPYRIGHT 2011 ACS on STN (Continued)  
nitrophenyl)methyl]- (CA INDEX NAME)



```
08.CITING REF COUNT: 18  THERE ARE 18 CAPLUS RECORDS THAT CITE THE
                        RECORD (18 CITINGS)
REFERENCE COUNT: 24  THERE ARE 24 CITED REFERENCES AVAILABLE F
THIS
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT
```

LA ANSWER 6 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 2005:985324 CAPLUS  
 DOCUMENT NUMBER: 143:272565  
 TITLE:  
 pharmaceutical combination comprising a sulfonamide  
 INVENTOR(S): KayaKiri, Hiroshi; Kato, Takeshi; Manoura, Hideaki;  
 Hiroseki, Jiro  
 PATENT ASSIGNEE(S): Fujiyama Pharmaceutical Co. Ltd., Japan  
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.  
 CODEN: USXKXO

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


[illegible]

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MNPAT 143:272565  
AB This invention provides a pharmaceutical combination containing a sulfonamide

or a salt and pharmaceutical selected from the group consisting of an  $\alpha$ -glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide. The blood glucose level of a patient showed greater decrease by the combined administration of the test compound and a biguanide.

IT 27 275381-12-9  
ML INC (Pharmacological activity); THW (Therapeutic use); SIGL (Biological study) (Uses) (Data)  
(Pharmaceutical combination comprising sulfonylurea)

EN 27 275381-12-9 CAPSULE  
CN Carbanic acid,  
4-chloro-4-[2-methyl-5-[[[pentyl(oxy)amino]carbonyl]-2H-indazol-4-yl]-5-pyridin-3-yl]methyl]phenyl methyl-, ethyl ester (PCI)  
[CA INDEX NAME]




16 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM  
 ACCESSION NUMBER: 2005:979654 CAPLUS  
 DOCUMENT NUMBER: 143:264925  
 TITLE: Preparation of imidazo[4,5-b]pyridine derivatives as GPR4 receptor antagonists  
 INVENTOR(S): Iida, Kyochoh; Otsuka, Nobumasa; Kuboyama, Takeshi; Arai, Hiroshi; Watanabe, Akiko; Saito, Mayumi  
 INVENTOR(S): Naoko Hatanabe, Hirochiko Takada, Hiromichi Saito, Jun Koyama, Makoto Koyama Co., Ltd., Japan  
 PATENT ASSIGNOR(S): PCT Int. Appl., 215 pp.  
 SOURCE: CORDIS FRAXED  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	FIRM	DATE	APPLICATION NO.	DATE
WO 2005:042905	AL	2005-09-09	WO 2005-JP3687	2005-02-25
WI, ME, AG, AU, AM, AT, AU, BG, BR, BY, CA, CH, CN, CO, CP, CZ, DE, EP, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, LT, LU, LV, MD, MG, MK, MN, MU, MY, NI, NO, NZ, OM, OS, PE, PL, PT, RU, SC, SE, SG, SI, SK, SM, ST, TH, TM, TR, TT, TS, UA, US, VE, VN, YU, ZA, ZM, ZW				

PRIORITY APPL. INFO.: JP 2004-50933 A 2004-02-26

OTHER SOURCE(S): MARPAT 143:264925

CI 2004-307947 A 2004-10-22



A3 The title compds. I [wherein R1 = H, halo, NR2, etc.; R2-R4 = independently R, halo, CH3, etc.; Y = H or (un)substituted CH2; X = (un)substituted NR, Si, or independently Y or (un)substituted CH2; W = NO2, Cl, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPCR) antagonists

for the treatment of neutrophil inflammation. For example, the compound was prepared in a multi-step synthesis. II inhibited 98% of human GPR4


the concentration of 1 μM.

863877-47-3P 863877-48-3P 863877-49-3P  
 R1a: RCT (Reagent); R1b: [Synthetic preparation]; PREP (Preparation); RACT (Reagent or reagent)


intermediate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists)

863877-47-3 CAPLUS


CH 3R-Imidazo[4,5-b]pyridine, 2-ethyl-1-[4-(4-nitro-1-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)



863877-48-9 CAPLUS  
 CH Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3R-imidazo[4,5-b]pyridin-3-yl)methyl]-2-nitro- (CA INDEX NAME)




863877-49-0 CAPLUS  
 CH 1,2-Benzenediamine, 4-[(2-ethyl-5,7-dimethyl-3R-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)  
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS  
 FORMAT




RN 864171-68-6 CAS/US  
 C21 Methanone,  
 [trans-4-{[4-{(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl}phenyl]amino}cyclohexyl]-1-pyrrolidinyl- (CA INDEX 88)




864171-71-2 CAPLUS  
 3-Piperazinecarboxylic acid, 4-[[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]carboxyl]-1,4-dimethyl]ethyl] ester (CA INDEX NAME)

Relative stereochemistry.



864171-72-2 CAPLUS  
 Methanone, trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1-piperidyl- (CA INDEX NAME)

Relative stereochemistry.




864171-74-4 CAPLUS  
 Methanone, trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-4-(hydroxymethyl)-1-piperidyl- (CA INDEX NAME)

Relative stereochemistry.


864171-81-3 CAPLUS  
 Methanone, trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-4-(4-morpholinyl)-1-piperidyl- (CA INDEX NAME)

Relative stereochemistry.




864171-83-5 CAPLUS  
 Methanone, 4-methyl-3-piperidyl trans-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




864171-92-4 CAPLUS  
 Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans (CA INDEX NAME)

Relative stereochemistry.




864171-76-4 CAPLUS  
 Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(3-pyrrolidinyl)ethyl]-, trans (CA INDEX NAME)

Relative stereochemistry.




864171-79-3 CAPLUS  
 Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans (CA INDEX NAME)

Relative stereochemistry.




864171-84-5 CAPLUS  
 Cyclohexanecarboxamide, 4-[[4-[(2,5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans (CA INDEX NAME)

Relative stereochemistry.




864171-89-2 CAPLUS  
 6-Piperidynamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




864172-00-9 CAPLUS  
 3-Piperidinecarboxylic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


16 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)  
bipyridin-3-ylmethylphenylamino)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




EN 064172-21-0 CAPLUS  
CN 4-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethylphenylamino)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



EN 064172-22-1 CAPLUS  
CN 1,4-Dioxaspiro[4.5]decan-8-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




EN 064172-04-5 CAPLUS  
CN Cyclohexanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino)methyl]-, ethyl ester, trans- (CA INDEX NAME)




EN 064172-07-6 CAPLUS  
CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]-, ethyl ester, trans- (CA INDEX NAME)

16 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




EN 064172-29-1 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.



EN 064172-29-2 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.




EN 064172-30-5 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2,5-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.


16 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




EN 064172-36-7 CAPLUS  
CN 6-Piperidinemethanamine, N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]-, ethyl ester, cis- (CA INDEX NAME)



EN 064172-33-6 CAPLUS  
CN 1-Piperidinesulfoic acid, 4-[[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




EN 064172-24-7 CAPLUS  
CN 6-Piperidinemethanamine, N-[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]-, ethyl ester, cis- (CA INDEX NAME)



EN 064172-27-0 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, cis- (CA INDEX NAME)


Relative stereochemistry.

16 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




EN 064172-31-6 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




EN 064172-31-6 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.



EN 064172-35-0 CAPLUS  
CN Cyclohexanecarboxylic acid, 4-[[4-[(2-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




```


001 064172-37-2  CAPLOS
002 Methazone, [c1cc-4-[[4-[[2-ethyl-5,7-dimethyl-3H-imid
      yl)methyl]phenyl]amino]oxy]cyclohexyl](4-methyl-1-piper
      NAME)

```

### Relative stereochemistry




CH Methazone, [cis-4-[[[4-[[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-4-morpholinyl]- (CA INDEX NAME)




FN 064172-40-7 CAPLOS  
 CN Methanone, [cis-4-[[4-[[2-ethyl-1,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1-pyrrolidinyl- (CA INDEX NAME)

Relative stereochemistry



JN 064172-44-2 CAPLUS  
 C2 Methanone, (4-methyl-1-piperazinyl) [cis-4-[4-[(2,5,7-trimethyl-2H-  
 imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)- (CA INDEX  
 NAME)


Relative stereochemistry.



```


R01 044172-53-0 CAPLOS
C01 Methanone, 4-morpholinyl[cis-4-[[4-[[2,5,7-trimethyl-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

```



HN 064172-53-2 CAPLOS  
 CN Methanone, [4-(hydroxymethyl)-1-piperidinyl]ois-4-[[4-[[2,5,7-trimeth-  
 3H-indazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)cyclohexyl]- (CA  
 NAME)

TABLE 7




71	04:10:70-93:69	04:10:70-94:79	04:10:70-97:93
72	04:11:00-93:69	04:11:00-94:79	04:11:00-97:93
73	04:11:02:70	04:11:02:80	04:11:02:93
74	04:11:03:40	04:11:03:50:139	04:11:03:10:20
75	04:11:03:50	04:11:03:50:139	04:11:03:10:20
76	04:11:10:40	04:11:10:11:99	04:11:10:08:29
77	04:11:13:31:9	04:11:13:31:9	04:11:13:31:9
78	04:11:15:40	04:11:17:1:19	04:11:17:28:49
79	04:11:15:40	04:11:17:1:19	04:11:17:28:49
80	04:11:15:40	04:11:17:23:39	04:11:17:23:39
81	04:11:15:40	04:11:17:23:39	04:11:17:23:39
82	04:11:17:28:49	04:11:17:28:49	04:11:17:30:20
83	04:11:32:31:29	04:11:32:31:29	04:11:32:31:29
84	04:11:32:31:29	04:11:32:35:79	04:11:32:35:79
85	04:11:32:35:79	04:11:32:35:79	04:11:32:35:79
86	04:11:32:35:79	04:11:32:35:79	04:11:32:35:79
87	04:11:32:40:40	04:11:32:41:59	04:11:32:42:69
88	04:11:32:41:59	04:11:32:41:59	04:11:32:41:59
89	04:11:32:40:40	04:11:32:47:19	04:11:32:47:19
90	04:11:32:40:40	04:11:32:47:19	04:11:32:47:19
91	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
92	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
93	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
94	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
95	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
96	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
97	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
98	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
99	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
100	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
101	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
102	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
103	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
104	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
105	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
106	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
107	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
108	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
109	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
110	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
111	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
112	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
113	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
114	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
115	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
116	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
117	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
118	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
119	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
120	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
121	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
122	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
123	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
124	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
125	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
126	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
127	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
128	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
129	04:11:32:47:19	04:11:32:47:19	04:11:32:47:19
130	04:11:3		

064172-50-5P    064172-52-5P    064172-54-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TEU  
 (Therapeutic use); BIO (Biological study); PREP (Preparation); USES  
 (Uses)  
 [drug candidate; preparation of amidazo[4,5-b]pyridine derivs. as GPR4  
 receptor antagonists for treatment of neurophilic inflammation]

864] TC-95-6 CAPL/38


C03 Benzanide, N-[4-[(2-ethyl-5,7-dimethyl-7H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-fluoro- (CA INDEX NAME)



```

NN      864170-96-7  CAPLUS
CN      Benzamide,
2-chloro-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]- (CA INDEX NAME)


```



```

RN  864170-97-8  CAPLOS
CH  Benzanide, N-[4-[12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)- (CA INDEX NAME)


```




```

RN      864170-98-9  CAPLUS
CN      Benzanide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methoxy-  (CA INDEX NAME)

```




IN 864170-99-0 CASREG  
 CH Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methyl- (CA INDEX NAME)




```

321 864171-00-6 CAMPUS
322 Acetanide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-
    ylmethyl)amino]-2-methoxy- (CA INDEX NAME)

```




02 Benzamide, N-[4-[12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl]ethyl]phenyl]-3-(trifluoroethyl)- (CA INDEX NAME)




```

NN      864171-02-8  CAPLUS
CN      Benzamide,
4-butoxy-N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]- (CA INDEX NAME)


```




RN 064171-03-9 CAPUS  
 CN Benzeneacetanide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methoxy- (CA INDEX NAME)



RXN 864171-00-4 CAPLOS  
 CN Cyclopentanecarboxamide, N-[4-[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX SUMME)




RN 864171-09-5 CASUS  
 CN Cyclopentanepropanamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




```

F20 864171-10-8 CAPLUS
C20 2-Furanicarboxamide,
N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]phenyl]- (CA INDEX NAME)

```




R# 864171-11-9 CAS#88  
 C# 1-Naphthalenecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



```

NN  864171-04-0  CAPLUS
CN  Acetanide, N-[4-[12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-
    ylmethyl]benzyl]- (CA INDEX NAME)


```



```

F01  064171-05-2  CAPLOS
C01  Acetanide, N-[4-[12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]benzyl]-2-methoxy- (CA INDEX NAME)


```



```


FN  864171-06-2  CAPLOS
CN  Propanamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)

```



FN 064171-07-3 CAPLOS  
 CN Cyclopropanecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-2H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-phenyl-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



```

NN  864171-12-0 CAPLUS
CN  2-Thiophenecarboxamide, N-[4-|2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
b|pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)


```




```

FH 064171-13-1 CAPLOS
CN 2-Thiopheneacetanide,
N-[4-(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-
3-yl)methyl]phenyl)- (CA INDEX NAME)


```




EN 864171-14-2 CAPLOS  
 CH 3-Pyridinecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-2H-anidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




EN 864171-15-3 CAPLOS  
 CN 1,3-Benzodioxole-5-carboxamide,  
 N-[4-[2-ethyl-5,7-dimethyl-2H-imidazo[4,5-  
 b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-16-4 CAPLUS  
CN Cyclopropanecarboxamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-17-5 CAPLUS  
CN Triethylamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-18-6 CAPLUS  
CN Benzamide, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-19-7 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-24-4 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-25-5 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-26-6 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-27-7 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-20-0 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-21-1 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-22-2 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



84171-23-3 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-28-8 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-29-9 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)


Relative stereochemistry.




84171-30-2 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-31-3 CAPLUS  
CN Urea, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




84171-30-4 CAPLUS  
CN Urea, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-N'-heptyl- (CA INDEX NAME)




84171-33-5 CAPLUS  
CN Urea, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-N'-[4-(fluorophenyl)]- (CA INDEX NAME)




84171-34-6 CAPLUS  
CN Carbamic acid, [4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-, methyl ester (PCT) (CA INDEX NAME)




84171-35-7 CAPLUS  
CN Carbamic acid, [4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-, ethyl ester (PCT) (CA INDEX NAME)




84171-40-4 CAPLUS  
CN 2-Proparsulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]- (CA INDEX NAME)




84171-41-5 CAPLUS  
CN Benzenesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]- (CA INDEX NAME)




84171-42-6 CAPLUS  
CN Benzenesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-4-methoxy- (CA INDEX NAME)




84171-43-7 CAPLUS  
CN Benzenesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-4-fluoro- (CA INDEX NAME)




84171-36-8 CAPLUS  
CN Carbamic acid, [4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-, 2-methylpropyl ester (PCT) (CA INDEX NAME)




84171-37-9 CAPLUS  
CN Carbamic acid, [4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-, hexyl ester (PCT) (CA INDEX NAME)




84171-38-0 CAPLUS  
CN Carbamic acid, [4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-, 4-methylphenyl ester (PCT) (CA INDEX NAME)




84171-39-3 CAPLUS  
CN 1-Butanesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]- (CA INDEX NAME)




84171-44-8 CAPLUS  
CN Benzenesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




84171-45-9 CAPLUS  
CN 2-Naphthalenesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]- (CA INDEX NAME)




84171-46-0 CAPLUS  
CN Benzenesulfonamide, N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]-3-nitro- (CA INDEX NAME)




84171-47-3 CAPLUS  
CN Benzenesulfonamide, 2,5-dichloro-N-[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]- (CA INDEX NAME)




RD 864171-48-2 CAPLUS  
 CN Benzenesulfonamide,  
 N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RD 864171-49-3 CAPLUS  
 CN 2-Naphtholbenzenesulfonamide,  
 5-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RD 864171-52-6 CAPLUS  
 CN 2-Naphtholbenzenesulfonamide, N-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RD 864171-53-7 CAPLUS  
 CN Benzenesulfonamide,  
 N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RD 864171-58-4 CAPLUS  
 CN Benzenesulfonamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RD 864171-62-8 CAPLUS  
 CN Benzenesulfonamide, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)

CH 1  
 CHD 864171-63-5  
 CHD C29 K36 106




CH 2  
 CHD 110-517-8  
 CHD C4 R4 04  
 Double bond geometry as shown.


RD 864171-61-8 CAPLUS  
 CN 4-Piperidinebenzenesulfonamide, N-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-methyl]- (CA INDEX NAME)




RD 864171-52-8 CAPLUS  
 CN Benzenesulfonamide,  
 N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




RD 864171-53-9 CAPLUS  
 CN Benzenesulfonamide,  
 N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-methyl- (CA INDEX NAME)




RD 864171-54-0 CAPLUS  
 CN Benzenesulfonamide, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)



RD 864171-55-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)




RD 864171-62-0 CAPLUS  
 CN Benzenesulfonamide, N-cyclohexyl-4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RD 864171-66-4 CAPLUS  
 CN Benzenesulfonamide, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[trans-4-[(4-methyl-3-piperidinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RD 864171-69-7 CAPLUS  
 CN Benzenesulfonamide, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[trans-4-[(1-piperidinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RD 864171-70-6 CAPLUS  
 CN Benzenesulfonamide, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[trans-4-[(1-piperidinyl)methyl]cyclohexyl]- (CA INDEX NAME)  
 Relative stereochemistry.






Relative stereochemistry.




RD 864171-91-5 CAPLUS  
 CH Methanone, trans-4-[[4-[(2-ethyl-7-methyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1-piperidin-3-ylmethyl-1-phenyl-1-amine (CA INDEX NAME)

Relative stereochemistry.




RD 864171-92-6 CAPLUS  
 CH Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-7-methyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-8-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RD 864171-93-7 CAPLUS  
 CH 4-Morpholinemethanamine, N-[[trans-4-[[4-[(2-ethyl-7-methyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.




RD 864171-99-3 CAPLUS  
 CH [1,4'-Bipiperidin]-4-amine, N-[[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]-1'-methyl- (CA INDEX NAME)




RD 864172-03-2 CAPLUS  
 CH Ethanone, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-1-phenyl- (CA INDEX NAME)



RD 864172-04-3 CAPLUS  
 CH [1,4'-Bipiperidin]-4-amine, N-[[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]-1'-methyl- (CA INDEX NAME)




Relative stereochemistry.




RD 864171-95-3 CAPLUS  
 CH Methanone, trans-4-[[4-[(2,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]-1-piperidin-3-ylmethyl-1-phenyl-1-amine (CA INDEX NAME)

Relative stereochemistry.




RD 864171-96-0 CAPLUS  
 CH Cyclohexanecarboxamide, 4-[[4-[(2,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-8-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RD 864171-97-1 CAPLUS  
 CH 4-Morpholinemethanamine, N-[[trans-4-[[4-[(2,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)


Relative stereochemistry.



RD 864172-09-8 CAPLUS  
 CH Methanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-1-piperidin-3-ylmethyl-1-phenyl-1-amine (CA INDEX NAME)

CH 1

CH 864172-08-7  
 CH 864172-08-7




CH 2

CH 110-17-8  
 CH 864172-08-7


Double bond geometry as shown.

CH 864172-08-7  
 CH 864172-08-7


RD 864172-10-1 CAPLUS  
 CH Cyclohexanecarboxamide, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-1-piperidin-3-ylmethyl-1-phenyl-1-amine (CA INDEX NAME)




FN 864172-11-2 CAPLUS  
 CH Cyclohexanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]methyl]-, trans- (CA INDEX NAME)  
 Relative stereochemistry.




FN 864172-12-3 CAPLUS  
 CH 2E-Pyraz-4-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- (CA INDEX NAME)




FN 864172-13-4 CAPLUS  
 CH 4-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




FN 864172-14-5 CAPLUS  
 CH 2E-Pyraz-4-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]tetrahydro- (CA INDEX NAME)



FN 864172-15-6 CAPLUS



FN 864172-21-4 CAPLUS  
 CH Cyclohexanone, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)  
 Relative stereochemistry.




PAGE 1-A




PAGE 2-A

FN 864172-22-5 CAPLUS  
 CH Methanone, (trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)(4-methyl-3-piperazinyl)- (CA INDEX NAME)


CH 6-Piperidinemethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-(1-methylpiper-1-yl)- (CA INDEX NAME)




FN 864172-17-8 CAPLUS  
 CH 6-Piperidinemethanamine, 3-(tetrahydro-2H-pyran-4-yl)-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



FN 864172-18-9 CAPLUS  
 CH 6-Piperidinemethanamine, 3-methyl-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




FN 864172-19-0 CAPLUS  
 CH [3,4'-Bipiperidino]-4-methanamine, 3'-methyl-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




FN 864172-20-3 CAPLUS  
 CH 6-Piperidinemethanamine, 3-(1-methylpiper-1-yl)-N-[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)



Relative stereochemistry.




FN 864172-25-8 CAPLUS  
 CH [2,4'-Bipiperidino]-4-methanamine, N-[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1'-methyl- (CA INDEX NAME)




FN 864172-32-7 CAPLUS  
 CH Methanone, (trans-4-[[4-[(3-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl)(4-methyl-3-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




FN 84172-33-8 CAPLUS  
 CN Cyclohexanecarboxamide, 4-[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-[4-morpholinyl]ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




FN 84172-34-9 CAPLUS  
 CN Cyclohexanecarboxamide, 4-[[4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-N-[2-[1-pyrrolidinyl]ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




FN 84172-43-0 CAPLUS  
 CN Benzenamine, N-[[cis-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[cis-4-[(1-pyrrolidinyl)methyl]cyclohexyl]-, ethanedioate

Relative stereochemistry.



FN 84172-45-5 CAPLUS  
 CN Benzenamine, N-[[cis-4-[[4-methyl-1-piperazinyl)methyl]cyclohexyl]-4-[[2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




FN 84172-46-2 CAPLUS  
 CN Cyclohexanecarboxamide, N-[2-[(4-morpholinyl)ethyl]-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.


FN 84172-36-1 CAPLUS  
 CN Cyclohexanecarboxylic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



FN 84172-38-3 CAPLUS  
 CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[cis-4-[[4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




FN 84172-42-9 CAPLUS  
 CN Benzenamine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[[cis-4-[(4-morpholinyl)methyl]cyclohexyl]-, ethanedioate (2:1) (CA INDEX NAME)

CH 1


CHN 84172-41-8

CHP C28 H29 N5 O

Relative stereochemistry.



CH 2




FN 84172-45-5 CAPLUS  
 CN 4-Morpholinethanamine, N-[[cis-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]-, ethanedioate (1:1) (CA INDEX NAME)

CH 1

CHN 84172-47-4

CHP C29 H42 N6 O

Relative stereochemistry.



CH 2

CHN 344-62-7

CHP C2 H2 O4


Relative stereochemistry.

CH 1

CHN 84172-49-4 CAPLUS

CH Methanone, (4-[(4-morpholinyl)-1-piperidinyl]oxy)-4-[[4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



84172-58-9 CAPLUS

CH Benzoxazine, 4-[[4-((2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]cyclohexylmethyl]- (CA INDEX NAME)


Relative stereochemistry.



84172-52-1 CAPLUS

CH Benzoxazine, 4-[[4-((2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]cyclohexylmethyl]- (CA INDEX NAME)


Relative stereochemistry.



84172-54-3 CAPLUS


CH 4-((2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenylamino]cyclohexylmethyl]- (CA INDEX NAME)

Relative stereochemistry.



84172-62-3 CAPLUS


CH Benzoic acid, 4-[[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]- (CA INDEX NAME)



84172-69-0 CAPLUS

CH Cyclohexanecarboxylic acid, 4-[[4-((2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.



84172-72-4 CAPLUS

CH Cyclohexanecarboxylic acid, 4-[[4-((2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



84172-73-6 CAPLUS

CH Cyclohexanecarboxylic acid, 4-[[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



177421-60-4P 177421-61-5P

84172-62-3P 84172-69-0P

84172-72-4P 84172-74-7P


84172-76-9P 84172-77-0P

84172-79-1P 84172-80-5P

84172-82-7P 84172-86-7P


84172-92-9P

Me: RCT (Reactant); STN (Synthetic preparation); FREE (Preparation); RACT (Reactant or reagent)  
(Intermediate preparation of imidazo[4,5-b]pyridine derivative as GPR4 receptor antagonist for treatment of neurophobic inflammation)  
CH 3H-imidazo[4,5-b]pyridine,  
2-ethyl-5,7-dimethyl-3-[[4-(4-nitrophenyl)methyl]- (CA INDEX NAME)




177421-61-5 CAPLUS

CH Benzoxazine, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



84172-61-2 CAPLUS


CH Benzoxazine, 2-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



84172-74-7 CAPLUS

CH Cyclohexanecarboxylic acid, 4-[[4-((2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



84172-75-8 CAPLUS

CH Cyclohexanecarboxylic acid, 4-[[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



84172-76-9 CAPLUS

CH Cyclohexanecarboxylic acid, 4-[[4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-phenyl]-amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.














RI 275393-24-2 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)



RI 275393-25-0 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-26-1 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-27-2 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)


RI 275393-31-8 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2-chloro-4-[(ethoxycarbonyl)amino]phenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-32-9 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2-chloro-4-[(ethoxycarbonyl)amino]phenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-33-0 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2-chloro-4-[(1-oxopropyl)amino]phenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-34-1 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2-chloro-4-[(1-oxopropyl)amino]phenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)





RI 275393-28-3 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2,4-dichloro-5-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-29-4 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(4-[(benzyl[1,3-dimethylamino]carboxyl)amino]-2-chlorophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-30-7 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2-chloro-4-[(1,3-dimethylamino]carboxyl)amino]phenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-35-2 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(4-[(benzyl[1,3-dimethylamino]carboxyl)amino]-2-chlorophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)



RI 275393-36-3 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(4-[(benzyl[1,3-dimethylamino]carboxyl)amino]-2-chlorophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




RI 275393-37-4 CAPLUS  
 CN 36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[(2-chloro-4-[(1,3-dimethylamino]carboxyl)amino]phenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)



16 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)


XX 275393-39-5 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[3-(3-dimethyl-1-oxobutyl)amino]phenyl]methyl]-2-methyl-  
(CA INDEX NAME)




XX 275393-40-9 CAPLUS

XX Imidazo[4,5-b]pyridine-5-carboxylic acid, 2-[[4-[[5-bromo-2-methyl-38-imidazo[4,5-b]pyridine-3-yl)methyl]-3-chlorophenyl]-, 1,3-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



XX 275393-41-0 CAPLUS

XX Calcium salt,  
[[4-[[5-bromo-2-methyl-38-imidazo[4,5-b]pyridine-3-yl)methyl]-3-chlorophenyl]-, 1,3-dimethylethyl ester (XC1) (CA INDEX NAME)



XX 275393-42-1 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



16 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)


XX 275393-54-5 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-  
(CA INDEX NAME)



XX 275393-48-7 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[ethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-,  
methyl ester (CA INDEX NAME)



XX 275393-50-1 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-  
(CA INDEX NAME)



XX 275393-52-3 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-,  
methyl ester (CA INDEX NAME)



16 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)

XX 275393-54-5 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-  
(CA INDEX NAME)




XX 275393-43-2 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-amino-2-chlorophenyl]methyl]-2-methyl-, methyl ester, hydrochloride  
(XC1) (CA INDEX NAME)



XX 275393-44-7 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-,  
methyl ester (CA INDEX NAME)



XX 275393-46-5 CAPLUS


XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-  
(CA INDEX NAME)



16 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)


XX 275393-54-5 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-  
(CA INDEX NAME)




XX 275393-56-7 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-[[4-bromo-1-oxobutyl]amino]-2-chlorophenyl]methyl]-2-methyl-,  
methyl ester (CA INDEX NAME)



XX 275393-62-5 CAPLUS


XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-,  
methyl ester (CA INDEX NAME)



XX 275393-66-9 CAPLUS

XX 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[2-chloro-4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)






275384-35-5 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,


3-[[2-chloro-4-[[1,1-dimethylheptyl]carboxyl]amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)



275384-36-6 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,


3-[[2-chloro-4-[[1,1-dimethylheptyl]carboxyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



275384-37-7 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,


3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



275384-37-1 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,


3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



275384-38-2 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,

3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)



275384-39-3 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,

3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)


275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)

275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)


275384-39-3 CAPLUS  
 CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,  
 3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



275384-39-3 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,


3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



275384-41-4 CAPLUS


CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxylic acid,

3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



275384-56-0 CAPLUS


CN Carbamic acid,

[4-[[5-bromo-2-methyl-3*H*-indazolo[4,5-*b*]pyridine-3-yl]methyl]-3-chlorophenyl]methyl-, methyl ester (9:1) (CA INDEX NAME)

275384-59-7 CAPLUS


CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxamide,

3-[[2-chloro-4-[[methyl]amino]phenyl]methyl]-2-methyl-4-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)



275384-63-2 CAPLUS


CN Carbamic acid,

[4-[[5-bromo-2-methyl-3*H*-indazolo[4,5-*b*]pyridine-3-yl]methyl]-3-chlorophenyl]methyl-, 1,1-dimethylethyl ester (9:1) (CA INDEX NAME)


275384-63-2 CAPLUS

CN 3*H*-Indazolo[4,5-*b*]pyridine-5-carboxamide,

16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)  
3-[[2-chloro-4-(ethylamino)phenyl]methyl]-2-methyl-N-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)



275383-73-2 CAPLOS  
CN Carbanic acid, [3-chloro-4-[[2,7-dimethyl-5-[[[4-methylphenyl]sulfonyl]amino]carbonyl]-6,8-pyridine-3-ylmethyl]phenyl]methyl-, 1,1-dimethylethyl ester (PCT) (CA INDEX NAME)



275383-33-4 CAPLOS  
CN 3H-Indazolo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-(methylamino)phenyl]methyl]-2,7-dimethyl-N-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)



275380-83-3P 275380-84-2P 275380-86-4P  
275380-87-3P 275380-88-6P 275380-90-0P  
275380-92-1P 275380-92-2P 275380-93-7P  
275380-94-4P 275380-95-1P 275380-96-6P  
275380-97-7P 275380-98-2P 275380-99-9P  
275381-21-0P 275381-26-1P 275381-27-6P  
275381-28-6P 275381-31-6P 275381-37-6P  
275381-39-0P 275381-50-3P 275381-52-7P  
275381-54-9P 275381-56-1P 275381-58-3P  
275381-60-7P 275381-63-8P 275381-63-0P  
275381-65-2P 275381-67-6P 275381-69-6P  
275381-71-6P 275381-73-2P 275381-75-4P  
275381-77-6P 275381-79-8P 275381-81-2P  
275381-83-4P 275381-85-6P 275381-87-8P  
275381-91-4P 275381-93-6P 275381-99-2P  
275382-01-0P 275382-03-3P 275382-05-1P  
275382-09-7P 275382-62-2P

N/A: N/A (Synthetic preparation); TDD (Therapeutic use); BOLD (Biological study); PZPZ (Preparation); USGS (Use); preparation of zirconium compounds as medicines)

275380-83-1 CAPLOS  
CN 3H-Indazolo[4,5-b]pyridine-3-carboxamide, N-(butylsulfonyl)-3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




275380-84-2 CAPLOS  
CN 3H-Indazolo[4,5-b]pyridine-3-carboxamide, N-(butylsulfonyl)-3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)


275380-85-6 CAPLOS  
CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[4-methylphenyl]sulfonyl]amino]carbonyl]-6,8-pyridine-3-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (PCT) (CA INDEX NAME)




16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)




275381-89-6 CAPLOS  
CN Carbanic acid, [4-[[2-[[[4-methylphenyl]amino]carbonyl]-2-methyl-3H-indazolo[4,5-b]pyridine-3-yl]methyl]-3-chlorophenyl]-, 1,1-dimethylethyl ester (PCT) (CA INDEX NAME)




275381-95-8 CAPLOS  
CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[1E]-1-pentenyl]sulfonyl]amino]carbonyl]-6,8-pyridine-3-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (PCT) (CA INDEX NAME)




275381-97-0 CAPLOS  
CN 3H-Indazolo[4,5-b]pyridine-5-carboxamide, 3-[[4-amino-2-chlorophenyl]methyl]-2-methyl-N-[[1E]-1-pentenyl]sulfonyl]- (CA INDEX NAME)




16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)



275380-86-4 CAPLOS  
CN 3H-Indazolo[4,5-b]pyridine-5-carboxamide, N-(butylsulfonyl)-3-[[2-chloro-4-(methylamino)phenyl]methyl]-2-methyl- (CA INDEX NAME)




275380-87-5 CAPLOS  
CN 3H-Indazolo[4,5-b]pyridine-5-carboxamide, 3-[[4-(butylmethylamino)-2-chlorophenyl]methyl]-N-(butylsulfonyl)-2-methyl- (CA INDEX NAME)




275380-88-6 CAPLOS  
CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[4-methylphenyl]sulfonyl]amino]carbonyl]-6,8-pyridine-3-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (PCT) (CA INDEX NAME)







275380-90-0 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-(dimethylamino)phenyl]methyl]-2-methyl-N-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




275380-91-1 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-(dimethylamino)phenyl]methyl]-2-methyl-N-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




275380-94-4 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-(dimethylamino)phenyl]methyl]-2-methyl-N-  
 [pentylsulfonyl]- (CA INDEX NAME)




275380-94-5 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-[[cyclohexylmethyl]methylamino]phenyl]methyl]-2-methyl-N-  
 [pentylsulfonyl]- (CA INDEX NAME)




275380-96-6 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-[[cyclohexylmethyl]methylamino]phenyl]methyl]-2-methyl-N-  
 [pentylsulfonyl]- (CA INDEX NAME)




275380-92-2 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-(methylpropylamino)phenyl]methyl]-2-methyl-N-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




275380-93-3 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[4-(butylmethylamino)-2-chlorophenyl]methyl]-2-methyl-N-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




275380-97-7 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-[[ethyldimethylamino]phenyl]methyl]-2,7-dimethyl-N-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




275381-10-7 CAPLUS  
 36-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[[2-chloro-4-[[2,2-dimethyl-1-methylpropylmethylamino]phenyl]methyl]-2-  
 methyl-N-[pentylsulfonyl]- (CA INDEX NAME)




275381-12-9 CAPLUS  
 Carbanic acid,  
 [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-  
 36-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, ethyl ester (CI)  
 (CA INDEX NAME)



275393-25-0 CAPLUS  
 CH Carbanic acid, 3-chloro-4-[[2-methyl-5-[[[pentylsulfonamido]carboxyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




275393-26-5 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-(methylanilino)phenyl]methyl]-2-methyl-8-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




275393-27-6 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-(methylpentylamino)phenyl]methyl]-2-methyl-8-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)



275393-27-8 CAPLUS  
 CH Carbanic acid, 3-chloro-4-[[2,7-dimethyl-5-[[[pentylsulfonamido]carboxyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




275393-29-0 CAPLUS  
 CH Carbanic acid, 3-chloro-4-[[2,7-dimethyl-5-[[[4-methylphenyl]sulfonyl]amino]carboxyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




275393-30-5 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2,4-dichloro-5-nitrophenyl]methyl]-2-methyl-8-(pentylsulfonyl)- (CA INDEX NAME)




275393-29-8 CAPLUS  
 CH Carbanic acid, 3-chloro-4-[[2,7-dimethyl-5-[[[pentylsulfonamido]carboxyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




275393-30-6 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-(methylpropylamino)phenyl]methyl]-2,7-dimethyl-8-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




275393-52-7 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2,4-dichloro-5-nitrophenyl]methyl]-2-methyl-8-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)



275393-54-9 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2,4-dichloro-5-(dimethylamino)phenyl]methyl]-2-methyl-8-(pentylsulfonyl)- (CA INDEX NAME)




275393-56-1 CAPLUS  
 CH 3H-Imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2,4-dichloro-5-(dimethylamino)phenyl]methyl]-2-methyl-8-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




275393-58-3 CAPLUS

16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)  
 CN 3*H*-imidazo[4,5-*b*]pyridine-5-carboxamide,  
 3-[[4-[(4-methylsulfonylmethylamino)-2-chlorophenyl]methyl]-2-methyl-*N*-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




ZN 275391-60-7 CAPLOS  
 CN Carbanic acid,  
 [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-  
 3*H*-imidazo[4,5-*b*]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl  
 ester, sodium salt (PC1) (CA INDEX NAME)




ZN 275391-61-5 CAPLOS  
 CN Carbanic acid,  
 [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-  
 3*H*-imidazo[4,5-*b*]pyridin-3-yl]methyl]phenyl]methyl-, propyl ester (PC1)  
 (CA INDEX NAME)


16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)



ZN 275391-69-6 CAPLOS  
 CN 3*H*-imidazo[4,5-*b*]pyridine-3-carboxamide,  
 3-[[4-[(4-methylsulfonylmethylamino)-2-chlorophenyl]methyl]-2-methyl-*N*-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




ZN 275391-71-0 CAPLOS  
 CN 3*H*-imidazo[4,5-*b*]pyridine-3-carboxamide,  
 3-[[4-[(4-methylsulfonylmethylamino)-2-chlorophenyl]methyl]-2-methyl-*N*-[[4-  
 methylphenyl]sulfonyl]- (CA INDEX NAME)




ZN 275391-73-2 CAPLOS  
 CN 3*H*-imidazo[4,5-*b*]pyridine-5-carboxamide,


16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)



ZN 275391-67-0 CAPLOS  
 CN Carbanic acid,  
 [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-  
 3*H*-imidazo[4,5-*b*]pyridin-3-yl]methyl]phenyl]methyl-, 1-methylethyl ester  
 (PC1) (CA INDEX NAME)




ZN 275391-67-2 CAPLOS  
 CN Carbanic acid,  
 [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-  
 3*H*-imidazo[4,5-*b*]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester  
 (PC1) (CA INDEX NAME)




ZN 275391-67-4 CAPLOS  
 CN Carbanic acid,  
 [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-  
 3*H*-imidazo[4,5-*b*]pyridin-3-yl]methyl]phenyl]methyl-, ethyl ester (PC1) (CA  
 INDEX NAME)

16 ANNEX 10 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)  
 3-[[2-chloro-4-[[3,3-dimethyl-5-oxobutyl]amino]phenyl]methyl]-2-methyl-*N*-  
 [[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




ZN 275391-75-4 CAPLOS  
 CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[3,3-  
 dimethyl-5-oxobutyl]amino]carbonyl]-3*H*-imidazo[4,5-*b*]pyridin-3-  
 yl]methyl]phenyl]methyl-, 1-methylethyl ester (PC1) (CA INDEX NAME)


Double bond geometry as shown.




ZN 275391-77-6 CAPLOS  
 CN Carbanic acid, [4-[[5-[[[butylsulfonyl]amino]carbonyl]-2-methyl-3*H*-  
 imidazo[4,5-*b*]pyridin-3-yl]methyl]-3-chlorophenyl]methyl-, 1-methylethyl ester  
 (PC1) (CA INDEX NAME)




ZN 275391-79-8 CAPLOS  
 CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[3,3-  
 dimethyl-5-oxobutyl]amino]carbonyl]-3*H*-imidazo[4,5-*b*]pyridin-3-  
 yl]methyl]phenyl]methyl-, ethyl ester (PC1) (CA INDEX NAME)



275381-81-2 CAPLUS  
CN Carbanic acid, [4-[[5-[[[pentylsulfonyl]amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]methyl-, ethyl ester (PC1) (CA INDEX NAME)




275381-82-4 CAPLUS  
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide, 3-[[4-amino-2-(chlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)




275381-83-4 CAPLUS  
CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, propyl ester (PC1) (CA INDEX NAME)

275381-89-2 CAPLUS  
CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[3E]-3-pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, ethyl ester (PC1) (CA INDEX NAME)





275381-91-9 CAPLUS  
CN Carbanic acid, [3-chloro-4-[[2-methyl-5-[[[3E]-3-pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]methyl-, 1,1-dimethylethyl ester (PC1) (CA INDEX NAME)


Double bond geometry as shown.




275381-92-1 CAPLUS  
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide, 3-[[2-chloro-4-[[[propylamino]carbonyl]amino]phenyl]methyl]-2-methyl-N-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




275381-87-8 CAPLUS  
CN Carbanic acid, [2-chloro-4-[[2-methyl-5-[[[pentylsulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]-, 3-methylethyl ester (PC1) (CA INDEX NAME)




275381-93-4 CAPLUS  
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide, 3-[[4-amino-2-(chlorophenyl)methyl]-N-(butylsulfonyl)-2-methyl- (CA INDEX NAME)



275381-93-6 CAPLUS  
CN Carbanic acid, [4-[[5-[[[pentylsulfonyl]amino]carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-3-chlorophenyl]-, ethyl ester (PC1) (CA INDEX NAME)




275381-92-3 CAPLUS  
CN 3H-imidazo[4,5-b]pyridine-5-carboxamide, 2-[[2-chloro-4-[[methyl (propylamino)carbonyl]amino]phenyl]methyl]-2-methyl-N-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)




275381-99-7 CAPLUS  
CN Carbanic acid, [4-methylphenyl]sulfonyl]-, 2-[[3-chloro-4-[[2-methyl-5-[[[4-methylphenyl]sulfonyl]amino]carbonyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]amino]ethyl ester (PC1) (CA INDEX NAME)







3N 275342-62-3 CAPLUS  
 CN Carboxylic acid,  
 [1-(4-chloro-4'-[2-methyl-5-[[[phenylsulfonyl]amino]carboxyl]-3H-imidazo[4,5-b]pyridine-3-yl)methyl]phenyl)methyl, phenylmethyl ester  
 (9CI) (CA INDEX NAME)



OR CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS

RECORD (5 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

benzimidazole, imidazole, 4,4-dihydrobenzimidazole and  
 2,3-dihydrobenzimidazole; R represents alkylene, oxygen, oxygenated lower  
 alkylene, etc.; and R2 represents optionally substituted aryl,  
 substituted


haphenyl, etc.] are prep. These compds. are useful as hypoglycemics  
 and have cAMP-PDE inhibitory, bronchodilating, vasodilating, smooth  
 muscle

cell inhibitory, and anti-allergic effects, etc.  
 3-[1,4-dimethoxybenzyl]-2-methyl-5-[[1-  
 pentasulfonyl(methylamino)benzo[b]furan at 10 mg/kg gave 71% decrease of  
 blood sugar in mice.


IT 219759-70-3P 219759-71-4P 219759-72-5P  
 219759-73-4P 219759-74-7P 219759-75-8P  
 219759-76-0P 219760-07-1P 219760-08-2P  
 219760-09-4P 219760-10-3P 219761-04-3P  
 219761-30-0P 219761-36-1P 219761-42-4P  
 219761-42-3P 219761-43-0P 219761-44-1P  
 219761-47-4P

RL NUC (Biological activity or effector, except adverse); R20  
 (Biological)  
 study, unclassified; SPH (Synthetic preparation); THP (Therapeutic use);  
 NUC (Biological study); PREP (Preparation); TRES (Uses)  
 [Preparation of heterocyclic moiety-containing sulfonamide compds. as  
 hypoglycemics]

3N 219759-70-3 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[1-(4-chloro-4'-[[phenylmethyl]amino]phenyl)methyl]-2-methyl-N-  
 (phenylsulfonyl)- (CA INDEX NAME)



3N 219759-71-4 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[1-(4-chloro-4'-[[phenylmethyl]amino]phenyl)methyl]-2-methyl-N-  
 (phenylsulfonyl)- (CA INDEX NAME)



3N 219759-72-5 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine-5-carboxamide,  
 3-[1-(4-chloro-4'-[[dimethylamino]phenyl)methyl]-2-methyl-N-  
 (phenylsulfonyl)- (CA INDEX NAME)

3-[1-(4-chloro-4'-[[dimethylamino]phenyl)methyl]-2-methyl-N-  
 (phenylsulfonyl)- (CA INDEX NAME)

ACCESSION NUMBER: 1999-134960 CAPLUS

DOCUMENT NUMBER: 150112506

TITLE: Preparation of heterocyclic moiety-containing

INVENTOR(S): Koyakita, Hiroshi; Abe, Yoshio; Hamashima, Hiroshi;

Sawada, Hiroshi; Minatani, Toshiyuki; Yanagaki,

Noriatsu; Oomura, Gensu; Shikama, Masahito;

Hirama, Takahiro; Oka, Teruo; Imoto, Takafumi

Pharmaceutical Co., Ltd., Japan; et al.

PCT Int. Appl., 472 pp.

CURRENT FIELD

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. FIRM DATE APPLICATION NO. DATE

WO 990312 A1 19990107 WO 1998-32877 19990614

W, M, AU, AT, BE, BR, CA, CH, CN, DE, DK, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, MC, MX, NL, NO, NZ, PL, PT, SE, SG, SI, SK, SW, TH, TR, TW, US, UK, ZA

NO, US, CA, CH, CN, DE, DK, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, MC, MX, NL, NO, NZ, PL, PT, SE, SG, SI, SK, SW, TH, TR, TW, US, UK, ZA

CA 2235229 A1 19990107 CA 1998-235239 19990614

AU 707345 A1 19990107 AU 1998-70745 19990614

AU 745081 B2 20020114 19990614

EP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614


JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614


JP 975742 A2 20000416 EP 1998-325715 19990614

JP 975742 A2 20000416 EP 1998-325715 19990614

16 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-8-(phenylsulfonyl)- (CA INDEX NAME)




RI 219760-06-3 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RI 219760-07-3 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-8-[[1(1R)-2-phenylethenyl)sulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.




RI 219760-09-4 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-nitrophenyl)methyl]-8-[[1(1R)-2-(4-

16 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)

RI 219761-35-0 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(4-(benzoylamino)-2-chlorophenyl)methyl]-2-methyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RI 219761-36-1 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(4-(benzoylamino)-2-chlorophenyl)methyl]-2-methyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RI 219761-41-8 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-methyl-1-oxodiphenylamino)phenyl)methyl]-2-methyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)


16 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
 ethenylphenyl)ethenyl)sulfonyl]-2,7-dimethyl- (CA INDEX NAME)  
 Double bond geometry as shown.



RI 219760-13-7 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(4-amino-2-chlorophenyl)methyl]-2-methyl-8-(phenylsulfonyl)- (CA INDEX NAME)




RI 219761-34-9 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-[(1-oxodiphenylamino)phenyl)methyl]-3-methyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




16 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)

RI 219761-42-9 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-(pentylamino)phenyl)methyl]-2-methyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RI 219761-43-0 CAPLUS  
 CN 38-Indazo[4,5-b]pyridine-5-carboxamide,  
 3-[(2-chloro-4-(methylpentylamino)phenyl)methyl]-2-methyl-8-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)







36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-((methylsulfonyl)amino)phenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)



36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-((methylsulfonyl)amino)phenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-nitrophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-, methyl ester (CA INDEX NAME)


36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-[[1-(oxobutyl)amino]phenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-nitrophenyl)methyl]-2,7-dimethyl-, methyl ester (CA INDEX NAME)



36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[(2-chloro-4-[[1-(oxobutyl)amino]phenyl)methyl]-2-methyl-, methyl ester  
(CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)


36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)



36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)




36-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
3-[[4-(benzoylmethylamino)-2-chlorophenyl)methyl]-2-methyl-, methyl  
ester (CA INDEX NAME)


16 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[phenylamino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




ZN 219767-92-7 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[methylphenyl]amino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)



ZN 219767-91-8 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[methylphenyl]amino]phenyl]methyl]-2-methyl- (CA INDEX NAME)



ZN 219767-94-9 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[phenylamino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




16 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)  
 ACCESSION NUMBER: 1993:497556 CAPLUS  
 DOCUMENT NUMBER: 129122581  
 ORIGINAL REFERENCE NO.: 129122524  
 TITLE: Process for producing 2-(methoxyphenyl)-4-quinolinecarboxylic acid  
 compounds  
 INVENTOR(S): Inoue, Yoshihisa; Endo, Hajime; Ishida, Naomichi; Nakamura, Norifumi; Sasaki, Jun; Ozawa, Takashi; Moriyasu, Yoshitomi; Tazaki, Atsuo; Wang, Shuzhong; Ito, Tomoko  
 PATENT ASSIGNEE(S): The Green Cross Corporation, Japan; Asahi Glass Co., Ltd.  
 SOURCE: U.S., 12 pp., Cont.-In-part of U.S. 5,478,832.  
 COPIES: 2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY AC. NUM. COUNT: 3  
 PATENT INFORMATION: 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 5760234	A	19900774	US 1995-540542	19951027
JP 0451642	A	19940125	JP 1993-123139	19930426
JP 0451659	A	19940125	JP 1993-125053	19930426
US 5478832	A	19951205	US 1993-55873	19930504
JP 0500264	A	19940322	JP 1993-146222	19930406
JP 241056	B2	19970620		
JP 0513942	A	19950514	JP 1994-264122	19941027
JP 0513992	A	19950514	JP 1994-264222	19941027
US 545882	A	19970209	US 1995-543965	19951010
PRIORITY APPL. INFO.:			JP 1993-147407	A 19920506
			JP 1992-176189	A 19920401
			US 1993-55873	A2 19930504
			JP 1994-264122	A 19941027
			JP 1994-264222	A 19941027
			US 1995-543965	A2 19951010


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LATE DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 129122581; MARPAT 129122581  
 AS Quinoline-2-yl benzoate and compounds, which are useful as intermediates of quinoline compound, having angiotensin II antagonist activity prepared by decarboxylating 2-(methoxyphenyl)-4-quinolinecarboxylic acid and compound in which a carboxyl group bonded to a ph. group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both lines may have one or more substituents inert to the decarboxylation reaction. Thus, 2-(2-methoxyphenyl)-6-methyl-4-quinolinecarboxylic acid (preparation given) was heated at 100°C for 1 h to give 2-quinoline-2-ylbenzoic acid.  
 IT 127425-00-4P 127425-00-5P 16555-58-0P  
 RI: NCT (Intermediate); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)  
 IF: Process for producing 2-(methoxyphenyl)-4-quinolinecarboxylic acid compound

NO 127425-00-4 CAPLUS


16 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)  
 CN 219767-95-0 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[phenylamino]phenyl]methyl]-2-methyl- (CA INDEX NAME)



ZN 219768-69-0 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[phenylamino]phenyl]methyl]-2-methyl-, methyl ester (CA INDEX NAME)




ZN 219768-01-1 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine-5-carboxylic acid,  
 3-[12-chloro-4-[[phenylamino]phenyl]methyl]-2-methyl- (CA INDEX NAME)




OS CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)  
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


16 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN (Continued)  
 CN 38-Imidazo[4,5-b]pyridine,  
 2-ethyl-5,7-dimethyl-3-[[4-nitrophenyl]methyl]- (CA INDEX NAME)



ZN 127423-03-5 CAPLUS  
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-38-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




ZN 165555-58-0 CAPLUS  
 CN 38-Imidazo[4,5-b]pyridine, 2-butyl-3-[[4-nitrophenyl]methyl]- (CA INDEX NAME)



OS CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT







CS CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

ACCESSION NUMBER: 1995/573496 CAPLUS  
DOCUMENT NUMBER: 122/574454  
ORIGINAL REFERENCE NO.: 122/572894, 572884  
TITLE: Preparation of [imidazopyridinomethyl]phenylphenylacetates and analogs as endothelin receptor antagonist  
INVENTOR(S): Chanane, Rajajit S.; Pritch, Kenneth J.; Vohrer, Daniel F.; Walsh, Thomas F.; Williams, David L., Jr.  
SOURCE: Merck and Co., Inc., USA  
Pat. Off. Pat. Appl., 198 pp.  
CODING: 004000  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	FIRD	DATE	APPLICATION NO.	DATE
GB 2276383	A	19940928	GB 1994-5332	19940217
US 5744120	A	19941210	US 1993-54456	19930219
PRIORITY APPL. INFO.			US 1993-54456	A 19930219


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L505 DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 122/574454




AB Title compds. [if Z = bond, 500-2(CR)0-5, O; Z = CO2H, 5-tetrazolyl(methyl), P(O)(OR), etc.; R1 = alk(en)yl, Ph, heteroaryl, etc.; R2, R10 = H, alk(en)yl, halo, alkoxy, etc.; R11, R12 = H, alkyl, Ph, etc.; Z = bond, O, CH2O, NH, etc.; Y = bond, O, Me, etc.; E = CH4(CR4)4(CR4), CR4(CR4)4H, CR4(CR4)4H, etc.; R4 = H, alkyl, halo, OR, etc.] were prepared. Thus, 5,4-ClMe3(CMe3O)CH5(CR4)2H8 (preparation given) was

condensed with 5,7-dimethyl-2-methylindazole[4,5-b]pyridine and the deprotected product esterified by 2-MeC6H4CH2CO2Me to give, after sapon., title compd. 17. 7 had IC50 of <50nM against endothelin binding at cloned human endothelin receptors *in vitro*.  
IT 137420-14-9P 137420-15-9P 138359-17-8P  
151954-14-2P 151954-15-2P 151954-16-4P  
151954-17-5P 151954-18-6P 151954-20-0P  
151954-21-2P  
R1, R2 (Biological activity or effector, except adverse); R3O (Biological)  
study, unclassified; SPM (Synthetic preparation); THO (Therapeutic use); R3CO (Biological study); PRP (Preparation); USES (Data)  
[Preparation of 1-imidazopyridinomethyl]phenylphenylacetates and analogs as endothelin receptor antagonists]


RN 137420-34-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl] (2-methyl-4-phenyl)- (CA INDEX NAME)




RN 137420-35-0 CAPLUS  
CN 2E-Tetrazole-5-methanamine, N-[(4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]-0-methyl-4-phenyl)- (CA INDEX NAME)




RN 138359-17-8 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl] (2-methylpropyl)amino]- (CA INDEX NAME)




RN 151954-14-2 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



RN 151954-15-3 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-16-4 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




RN 151954-17-5 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indazole[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)


16 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)  
bipyridin-3-ylmethylphenyl]-2-propen-1-ylamino]- (CA INDEX NAME)




151934-18-6 CAPLUS  
CH Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]propylamino]- (CA INDEX NAME)




151934-20-0 CAPLUS  
CH Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]propylamino]- (CA INDEX NAME)




151934-22-2 CAPLUS  
CH Benzenesulfonic acid,  $\omega$ -[cyclopropylmethyl][4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenylamino]- (CA INDEX NAME)




16 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)  
CH Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]methyl-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)



137421-64-8 CAPLUS  
CH Benzenesulfonic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-methyl-, (CA INDEX NAME)



137421-65-9 CAPLUS  
CH Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]methylamino]-, methyl ester (CA INDEX NAME)




137421-66-0 CAPLUS  
CH Carbanic acid, ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)

16 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)


137421-60-4P 137421-61-5P 137421-62-4P  
137421-63-7P 137421-64-5P 137421-65-9P  
137421-66-0P 137421-67-1P 137421-68-2P  
137421-69-3P 137421-70-6P 137421-71-1P  
137421-72-8P 137421-73-9P 137421-74-0P  
137421-75-1P 137421-76-2P 137421-77-3P  
151934-55-8P

Et: RCT (Reagent); HPL (Synthetic preparation); PREP (Preparation); NAUT (Nucleic acid);  
analogs  
[preparation of (imidazopyridinomethyl)phenoxylphenylacetates and  
as endothelin receptor antagonists)


137421-62-4 CAPLUS  
CH 3H-Imidazo[4,5-b]pyridine,  
2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]-  
(CA INDEX NAME)



137421-61-5 CAPLUS  
CH Benzenesulfonic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




137421-62-6 CAPLUS  
CH Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)




137421-63-7 CAPLUS


16 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)



137421-61-3 CAPLUS  
CH Benzenesulfonic acid, N-ethyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




137421-62-2 CAPLUS  
CH Benzenesulfonic acid,  $\omega$ -[ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]methylamino]-, methyl ester (CA INDEX NAME)




137421-69-3 CAPLUS  
CH Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl]propyl-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)







32 137421-70-6 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}-2-propen-1-ylamino)-, methyl ester (CA INDEX NAME)




32 137421-71-7 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)




32 137421-72-8 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)




32 137421-73-9 CAPLUS



32 137421-77-3 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)




32 151934-32-8 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)


CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)



32 137421-74-0 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)



32 137421-75-1 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)



32 137421-76-2 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-{[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}propylamino)-, methyl ester (CA INDEX NAME)

ACCESSION NUMBER: 1595364400  
 DOCUMENT NUMBER: 122187483

ORIGINAL REFERENCE NO.: 122187483, 34350a

TITLE: Facile, Regioselective Syntheses of N-Alkylated

2,3-Diaminopyridines and 2,4-Diaminopyridines

Pharma, Ish F., Weiser, Richard M., Lemt, Erik T.,

Bewton, Lloyd Lakin, David C.

Department of Chemistry, G. D. Searle Co., Skokie,

IL, 60077, USA

SOURCE: Journal of Organic Chemistry (1995), 60(4), 940-5

CODING: CODING: JSM: 0052-1282

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CSHBACT 122187483

AB Useful strategies are reported for the differentiation and selective

synthetic manipulations of amino groups at the 2- and 3-positions of

pyridines. It has been found that 2,3-diaminopyridine reacts with

aldehyde under reductive amination conditions to give predominantly the

N-2 alkylated product, which have been used for the regioselective

synthesis of N-1 substituted imidazo[4,5-b]pyridines. Investigations

using 2-formamido-3-aminoimidazole (13), synthesized in two steps from

2-amino-3-nitropyridine, show it to be a versatile intermediate for the

regioselective synthesis of either N-1 or N-2 substituted

imidazo[4,5-b]pyridines, depending upon the conditions employed. The

regioselective synthesis of 1,6-dihydropyridine in one step,

whereas reaction of 13 with alkyl halides in the presence of a suitable

base (e.g., cesium carbonate) yields the N-2 substituted amino

imidazo[4,5-b]pyridines. The generality of this synthetic method. as

noted.

17 161529-31-3P

NA: SPH (Synthetic preparation) PREP (Preparation)

(regioselective syntheses of alkylated diaminopyridines and

imidazopyridines)

32 161529-31-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

16 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 1519547127 CAPLUS  
 DOCUMENT NUMBER: 11212026  
 ORIGINAL REFERENCE NO.: 1224393a,4394a  
 TITLE: N-methyl indoleamine II (AII) receptor antagonists: N-substituted indoles, dihydroindoles, phenylaminoethylacetic acid and acylalanineamide-based

ATTORNEY(S): All receptor antagonists  
 Uharov, D. S.; Bentley, S. W.; Chang, E. R. L.; Lott, V. J.; Chen, T. J.; Kivlighn, S. D.; Simpson, G.; Siegel, F. W. S.; Greenberg, W. O.  
 CORPORATE SOURCE: March Res. Lab., Rahway, NJ, 07065, USA  
 SCIENCE: Chem., Struct. Biol., Proc. Res. Reg. Syst., 1983 (1984), Meeting Data 1993, 290-0. Editor(s): Balgley, Robert S.; Smith, John A. ASCON: London, Neth.

DOCUMENT TYPE: Conference  
 LANGUAGE: English  
 AB: The design and bio-, activity of new series of angiotensin II receptor antagonists derived from N-substituted indole, dihydroindole, phenylaminoethylacetic acid and acylalanineamide are presented.  
 IT: 151954-14-2 151954-15-3 151954-16-4  
 151954-17-5 151954-18-6 151954-19-7  
 151954-20-5 151954-20-9 151954-30-5  
 151954-37-9 151954-38-0 151954-39-1  
 151954-53-3  
 BL: RAC (Biological activity or effector, accept adverbs); RBD (Biological study, unclassified); PFP (Properties); RMD (Biological study) [structure-activity relationships of nonpeptide angiotensin II receptor antagonists]

RE: 151954-14-2 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)




RE: 151954-15-3 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-16-4 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]propylamino)- (CA INDEX NAME)


16 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RE: 151954-20-5 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)



RE: 151954-20-9 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-20-9 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-37-9 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)


16 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RE: 151954-34-4 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)



RE: 151954-17-5 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-18-6 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)



RE: 151954-12-7 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




16 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RE: 151954-20-0 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-29-1 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-39-1 CAPLUS  
 CH: Benzenesulfonic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]methylamino)- (CA INDEX NAME)




RE: 151954-53-3 CAPLUS  
 CH: 1-Tetraazolidinethanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-indol-4,5-b)pyridin-3-yl)methyl]phenyl]-N-methyl-N-phenyl)- (CA INDEX NAME)




16 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN  
 ACCESSION NUMBER: 1594-49965 CAPLUS  
 DOCUMENT NUMBER: 12115955  
 ORIGINAL REFERENCE NO.: 12115959A, 17545A  
 TITLE: Non-peptide angiotensin II receptor antagonists. 2. N-substituted (phenylamino)phenylacetic acids and sulfonylides. [Excerpt to document cited in CAPLUS (15-45194)]  
 AUTHOR(S): Bhansali, S.; Ragley, Scott M.; Chang, Raymond S.; L.; Lotti, Victor J.; Chen, Tsing Bau; Kavigh, D.; Singaro, Gloria J.; Siegl, Peter K. S.; Patchett, Arthur A.; Greenlee, William J.  
 CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA  
 SOURCE: Journal of Medicinal Chemistry (1994), 37(1), 1034  
 CORDIS NUMBER: 0022-3433  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB: The errors were not reflected in the abstract or the index entries.  
 IT 177421-62-4P 177421-72-5P 151954-46-4P  
 151954-47-1P 151954-48-2P 151954-49-3P  
 151954-50-4P 151954-51-7P  
 RI: RCT (Reactant); RPD (Synthetic preparation); PREP (Preparation); RMT (Reactant or reagent)  
 Preparation and alkylation (Exeratum)  
 RI 177421-62-6 CAPLUS  
 CN Carbamic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino-, methyl ester (CA INDEX NAME)




RI 177421-72-8 CAPLUS  
 CN Benzenecetic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino-, methyl ester (CA INDEX NAME)




RI 151954-46-6 CAPLUS  
 CN Benzenecetic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-2-methylphenyl]amino-, methyl ester (CA INDEX NAME)




RI 151954-47-1 CAPLUS  
 CN Benzenecetic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-2-methylphenyl]amino-, ethyl ester (CA INDEX NAME)




RI 151954-48-2 CAPLUS  
 CN Benzenecetic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl)amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RI 151954-49-3 CAPLUS  
 CN Benzenecetic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl)amino]-3,5-difluoro-, ethyl ester (CA INDEX NAME)



RI 151954-50-6 CAPLUS  
 CN Benzenecetic acid, 2-chloro-4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl)amino]-, ethyl ester (CA INDEX NAME)




RI 151954-51-7 CAPLUS  
 CN Benzenecetic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methylphenyl)amino]-3-methyl-, ethyl ester (CA INDEX NAME)




IT 177420-35-0P 177420-37-0P 151954-14-2P  
 151954-15-3P 151954-16-4P 151954-17-5P  
 151954-18-6P 151954-19-7P 151954-20-8P  
 151954-21-9P 151954-22-0P 151954-23-1P  
 151954-24-2P 151954-25-3P 151954-26-4P  
 151954-27-5P 151954-28-6P 151954-29-7P  
 151954-30-8P 151954-31-9P 151954-32-0P  
 151954-33-1P 151954-34-2P 151954-35-3P  
 151954-36-4P 151954-37-5P 151954-38-6P  
 151954-39-7P 151954-40-8P 151954-41-9P  
 RI: RMT (Biological activity or effector, except adenosine); RPD (Biological)


16 ANSWER 18 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)  
 study, unclassified; STM (Synthetic preparation); TSP (Therapeutic use);  
 STC (Toxicological study); PMS (Preparation); CSD (Data)  
 [prep. and antipotent 11 antagonist activity of, structure in  
 relation to (data)]  
 2N 151940-35-Q CAPLOS  
 CN 26-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methyl-2-phenyl- (CA INDEX NAME)



2N 151939-17-R CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methylpropylamino)- (CA INDEX NAME)




2N 151934-14-2 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)




2N 151934-13-3 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)


16 ANSWER 18 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)




2N 151934-20-0 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methylpropylamino)- (CA INDEX NAME)



2N 151934-22-2 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)




2N 151934-23-7 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino)- (CA INDEX NAME)




2N 151934-24-4 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino)- (CA INDEX NAME)


16 ANSWER 18 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)




2N 151934-16-4 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)



2N 151934-17-5 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino)- (CA INDEX NAME)




2N 151934-18-6 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)




2N 151934-13-7 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)- (CA INDEX NAME)




16 ANSWER 18 OF 29 CAPLOS COPYRIGHT 2011 ACS ON STM (Continued)




2N 151934-25-5 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino)- (CA INDEX NAME)



2N 151934-26-4 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino)- (CA INDEX NAME)




2N 151934-27-7 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino)- (CA INDEX NAME)




2N 151934-28-8 CAPLOS  
 CN Benzenecarboxylic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino)-2-methyl- (CA INDEX NAME)









20 151914-56-2 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino-, methyl ester (CA INDEX NAME)




20 151914-57-3 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]propylamino-, methyl ester (CA INDEX NAME)




20 151914-58-4 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino)-2-methyl-, ethyl ester (CA INDEX NAME)




20 151914-62-0 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[ethyl[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




20 151914-63-1 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[ethyl[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




20 151914-64-2 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino)-2,5-difluoro-, ethyl ester (CA INDEX NAME)




20 151914-69-8 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino)-2,5-difluoro-, ethyl ester (CA INDEX NAME)




20 151914-69-9 CAPLUS  
 CH Benzenesacetic acid, 2-ethoxy  $\omega$ -[ethyl[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)



20 151914-61-9 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[ethyl[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-methyl-, ethyl ester (CA INDEX NAME)



20 151914-62-0 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[ethyl[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)



20 151914-63-1 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[ethyl[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3,5-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)




20 151914-64-2 CAPLUS  
 CH Benzenesacetic acid,  $\omega$ -[4-[(12-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino)-2,5-difluoro-, ethyl ester (CA INDEX NAME)

16 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)

ACCESSION NUMBER: 1994:426465 CAPLUS  
DOCUMENT NUMBER: 121:26465  
ORIGINAL REFERENCE NO.: 121:4633a,4636a  
TITLE: Benzofuran based non-peptide antagonists of angiotensin II related to GR117299. Part IV: Indisopiridylbenzofurans  
AUTHOR(S): Judd, D. B.; Cardwell, M. S.; Ranchal, T. A.; Jack, T.

1; Pass, M.; Hubbard, T.; Dear, A. W.; Rutt, A. V.; Brown, J. E.; et al.  
CORPORATE SOURCE: Glaxo Group Ltd., Ware/Herts, HX1 2CP, UK  
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(1),  
723-8  
CODEN: BMCLDH; ISSN: 0960-894X

DOCUMENT TYPE: Journal  
LANGUAGE: English  
CS




AB The identification of a series of indisopiridylbenzofurans (1, R1 = H, Me, OMe, or CMe3) as potent, non-peptide antagonists of angiotensin II is described. Several of these compounds decrease the blood pressure in the renal artery ligated rat model of hypertension after oral administration. (1, R1 = Me or CMe3) have high bioavailability and metabolic stability and low plasma clearance in rats.


IT 151930-55-3 151930-56-6  
R1: R100. (Biological study)  
and (antihypertensive and angiotensin II receptor antagonist activities  
of)

PH 151930-55-3 CAPLUS  
CH Methanesulfonamide, N-[3-bromo-5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-benzofuranyl]-1,1,1-trifluoro- (CA INDEX NAME)

16 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)




PH 151930-58-8 CAPLUS  
CH Methanesulfonamide, N-[3-bromo-5-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-benzofuranyl]-1,1,1-trifluoro- (CA INDEX NAME)




OS\_CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITATIONS)

16 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)



PH 151930-56-6 CAPLUS  
CH Methanesulfonamide, N-[3-bromo-5-[(2-ethyl-5-(hydroxymethyl)-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-benzofuranyl]-1,1,1-trifluoro- (CA INDEX NAME)



IT 151930-57-7 151930-58-8  
R1: R100. (Biological study)  
and (antihypertensive and angiotensin II receptor antagonist activities  
of)

PH 151930-57-7 CAPLUS  
CH 3H-imidazo[4,5-b]pyridine-3-carboxylic acid,  
2-[[3-bromo-6-[(trifluoromethyl)sulfonyl]amino]-5-benzofuranyl]methyl]-2-ethyl-7-methyl- (CA INDEX NAME)


16 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM

ACCESSION NUMBER: 1994:260550 CAPLUS  
DOCUMENT NUMBER: 120:260550  
ORIGINAL REFERENCE NO.: 120:45017a,45020a

TITLE: Acidic phenols: a new class of potent nonpeptide angiotensin II receptor antagonists  
AUTHOR(S): Kim, Dongseop; Martin, Nathan S.; Tata, J. S.; Fitch, E.; Sharma, D.; Owen, R. J.; Lavoie, D.; Siegel, P. K. S.; Chang, R. S. L.; et al.

CORPORATE SOURCE: Dep. Exptl. Med. Res. Lab., Rahway, NJ, 07065, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(1),  
207-12  
CODEN: BMCLDH; ISSN: 0960-894X


DOCUMENT TYPE: Journal  
LANGUAGE: English  
CS



AB A series of imidazo[4,5-b]pyridine-based acidic phenols are exemplified as novel non-peptide AII receptor antagonists. O,o'-substituents which affect the acidity of the phenolic portion dramatically impact the activity of the compounds. The most potent antagonist in this series (1, IC50 = 5 nM, rabbit aorta) exhibited good in vivo potency after both i.v. and oral administration to conscious rats.

IT 151512-14-4F 151512-15-3F 151512-16-4F  
R1: R100. (Biological activity or effector, except adverse); R20  
(Biological study; unclassified); R30 (Synthetic preparation); R40 (Therapeutic use); R50 (Biological study); R60 (Preparation); R70 (Use) (preparation and angiotensin II antagonist activity of)


PH 151512-14-4 CAPLUS  
CH Phenol, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-nitro- (CA INDEX NAME)



PH 151512-15-5 CAPLUS




16 ANMER 20 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)  
 CH Phenol, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-hydro-6-[(2-propen-1-yl)- (CA INDEX NAME)



3H 151512-16-6 CAPLUS

CH Phenol, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-hydro-6-nitro- (CA INDEX NAME)




IT 151512-28-0P

RI NCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and dealkylation of)

3H 151512-30-2 CAPLUS

CH 3H-imidazo[4,5-b]pyridine,  
 2-ethyl-5,7-dimethyl-3-[(2-nitro-4-(2-propen-1-yl)phenyl)phenyl]- (CA INDEX NAME)



OS-CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
 (2 CITINGS)

16 ANMER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)  
 Incorporation of the acyl sulfonamide (CONSDS-Ph) for the COX of IV not only enhanced the ATI potency but also effected a marked increase in the ATI potency of VII (ATI IC50 = 0.74 μM of VI vs 0.4 μM of VII) and made it the most potent ATI antagonist in this study. Replacement of the COX of with the mononuclear tetraole resulted in VII (ATI IC50 = 15 μM) with a 2-fold loss in the ATI and a complete loss in the ATI binding affinity. (Phenylamino)phenylacetic acid IV demonstrated good oral activity in AII-infused mononuclear normotensive rats at an oral dose of


1-0 mg/kg by inhibiting the pressor response for >6 h. Aryl sulfonamides VII-IX displayed excellent in vivo activity by blocking the ATI-induced pressor response for 36 h after oral administration in conscious rats at

4 3.5 mg/kg dose level. Both acyl sulfonamides VII and IX exhibited superior in vivo activity in rats compared to that of (phenylamino)phenylacetic acid IV.

IT 137421-62-6P 137421-72-8P 151954-46-0P  
 151954-47-1P 151954-48-2P 151954-49-3P  
 151954-50-4P 151954-51-7P


RI NCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and alkylation of)

3H 137421-62-6 CAPLUS  
 CH Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl-, 1,1-dimethyl ester (PCT) (CA INDEX NAME)



3H 137421-72-8 CAPLUS

CH Benzenesulfonic acid, ω-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)



3H 151954-46-0 CAPLUS

CH Benzenesulfonic acid, ω-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)

16 ANMER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)

ACCESSION NUMBER: 1594-45190 CAPLUS  
 DOCUMENT NUMBER: 120-45190  
 ORIGINAL REFERENCE NO.: 120-80474,0504

TITLE: Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides

author(s): Sharma, Rajjit S.; Bagley, Scott W.; Chang, Raymond S.; Lotfi, Victor J.; Chen, Tsing Ben; Kavilagin, Salah

COOPERATE SOURCE: D.J. Simons, Gloria J. Simons, Peter K. S.; Patchett, Arthur A.; Greenlee, William D.


SOURCE: J. Med. Chem. 1997, 40, 4239-49

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120-45190

CI




AB The design, synthesis, and biol. activity of a new class of highly potent non-peptide ATI receptor antagonists derived from N-substituted (phenylamino)phenylacetic acid and acyl sulfonamides which exhibit a high selectivity for the ATI receptor are described. A series of N-substituted (phenylamino)phenylacetic acids (I) and acyl sulfonamides (II) and a tetraole derivative (III) were synthesized and evaluated in the

in vitro ATI (rabbit aorta) and ATI2 (rat midbrain) binding assay. The (phenylamino)phenylacetic acids I (R = H) (VI) (ATI IC50 = 4 nM, ATI2 IC50 = 0.74 μM), I (R = allyl) (VII) (ATI IC50 = 5.3 nM, ATI2 IC50 = 0.49 μM), and I (R = Pr) (VIII) (ATI IC50 = 5.3 nM, ATI2 IC50 = 0.56 μM) were found to be the most potent ATI-selective ATI antagonists in the acid series. Incorporation of various substituents in the central and between Ph rings led to a decrease in the ATI and ATI2 binding affinity of the resulting compounds. Replacement of the carboxylic acid (COOH) in IV, V, and VI with the biotinamide acyl sulfonamide (CONSDSPh) resulted in a 15-70-fold increase in the ATI potency of II (R = H) (VII) (ATI IC50 = 0.9 nM, ATI2 IC50 = 0.2 μM), II (R = allyl) (VIII) (ATI IC50 = 1 nM, ATI2 IC50 = 2.9 μM), and II (R = Pr) (IX) (ATI IC50 = 0.8 nM, ATI2 IC50 = 0.42 μM) and yielded acyl sulfonamides with subnanomolar ATI activity.


16 ANMER 21 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)

CH 151954-47-1 CAPLUS  
 CH Benzenesulfonic acid, ω-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-methyl-, ethyl ester (CA INDEX NAME)




3H 151954-47-1 CAPLUS

CH Benzenesulfonic acid, ω-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-methyl-, ethyl ester (CA INDEX NAME)




3H 151954-48-2 CAPLUS

CH Benzenesulfonic acid, ω-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




3H 151954-49-3 CAPLUS


CH Benzenesulfonic acid, ω-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2,5-difluoro-, ethyl ester (CA INDEX NAME)




HN 151954-16-6 CAPLUS  
CN Benzenesacetic acid, 2-chloro-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)




HN 151954-51-7 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, ethyl ester (CA INDEX NAME)




IT 137420-31-0P 138059-17-0P 151954-14-2P  
151954-15-3P 151954-16-4P 151954-17-0P  
151954-18-6P 151954-19-7P 151954-20-0P  
151954-22-2P 151954-23-3P 151954-24-4P  
151954-25-3P 151954-26-6P 151954-27-7P  
151954-28-0P 151954-29-3P 151954-30-2P  
151954-31-3P 151954-32-4P 151954-33-3P  
151954-34-4P 151954-35-7P 151954-36-8P  
151954-37-9P 151954-38-0P 151954-39-1P  
R<sub>1</sub>, R<sub>2</sub> RAC [Biological activity or effects, except adverse]; RSU [Biological]




HN 151954-16-4 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)



HN 151954-17-5 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-yl]amino]- (CA INDEX NAME)




HN 151954-18-6 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




HN 151954-19-7 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)

study, unclassified); STN [Synthetic preparation]; TSP [Therapeutic use]; STN [Biological study]; TSP [Preparation]; TSP [Use]; [Prep. and angiotensin II antagonist activity of, structure in relation to]


HN 137420-35-0 CAPLUS  
CN 2H-Tetrazolo-5-methanamine, N-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methyl-4-phenyl]- (CA INDEX NAME)




HN 138359-17-0 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1-methylpropyl]amino]- (CA INDEX NAME)




HN 151954-14-2 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




HN 151954-15-3 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




HN 151954-20-0 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methylpropyl]amino]- (CA INDEX NAME)




HN 151954-22-2 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




HN 151954-23-3 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




HN 151954-24-4 CAPLUS  
CN Benzenesacetic acid, 4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]- (CA INDEX NAME)




151954-25-5 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino)- (CA INDEX NAME)




151954-26-6 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino)- (CA INDEX NAME)




151954-27-7 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]propylamino)- (CA INDEX NAME)




151954-28-8 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-methyl- (CA INDEX NAME)




151954-33-3 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-2-methyl- (CA INDEX NAME)




151954-34-6 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-2,5-difluoro- (CA INDEX NAME)




151954-35-7 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




151954-36-8 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




151954-29-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino)-2-methyl- (CA INDEX NAME)




151954-30-2 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




151954-31-3 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-3,5-difluoro- (CA INDEX NAME)




151954-32-4 CAPLUS  
CN Benzenesacetic acid, 2-chloro- $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-3,5-difluoro- (CA INDEX NAME)




151954-37-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-8-(phenylsulfonyl)- (CA INDEX NAME)




151954-38-0 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-8-(phenylsulfonyl)- (CA INDEX NAME)




151954-39-1 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)-8-(phenylsulfonyl)- (CA INDEX NAME)




- IT 137420-35-OP  
 RL: SYN (Synthetic preparation); PREP (Preparation)  
 Preparation and imide/acid activity of, structure in relation to  
 CN 137420-35-2 CAPLUS  
 CN 2B-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-methyl-5-phenyl-1H-imidazole-3-ylmethyl- (CA INDEX NAME)




- IT 137421-43-7P  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 Preparation and degradation of  
 CN 137421-83-7 CAPLUS  
 CN Carboxylic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl[methyl]-, 1,1-dimethyl-2-ethyl ether (ICI) (CA INDEX NAME)




- IT 137421-64-8P  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 Preparation and reaction of, with benzaldehyde and cyanide  
 CN 137421-64-8 CAPLUS  
 CN Benzeneamide, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methyl- (CA INDEX NAME)




- IT 151354-41-5 CAPLUS  
 CN 2B-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(2-methyl-4-nitrophenyl)methyl]- (CA INDEX NAME)




- IT 137421-65-3P 137421-68-2P 137421-71-7P  
 137421-73-2P 137421-75-2P 151354-32-8P  
 151354-51-3P 151354-54-2P 151354-55-3P  
 151354-56-2P 151354-57-2P 151354-58-4P  
 151354-59-3P 151354-60-8P 151354-61-9P  
 151354-62-9P 151354-63-2P 151354-64-2P  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 Preparation and amphoteric activity of  
 CN 137421-65-3 CAPLUS  
 CN Benzenesulfonic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)methyl]amino-, methyl ester (CA INDEX NAME)




- IT 137421-68-2 CAPLUS  
 CN Benzenesulfonic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)methyl]amino-, methyl ester (CA INDEX NAME)




- IT 137421-61-5P 151354-44-8P  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 Preparation and reaction of, with bromophenylacetic acid derivative  
 CN 137421-61-5 CAPLUS  
 CN Benzenesulfonic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




- IT 151354-44-8 CAPLUS  
 CN Benzenesulfonic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methyl- (CA INDEX NAME)




- IT 137421-60-4P 151354-43-5P  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 Preparation and reduction of  
 CN 137421-60-4 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]- (CA INDEX NAME)




- IT 137421-71-7 CAPLUS  
 CN Benzenesulfonic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)methyl]amino-, methyl ester (CA INDEX NAME)




- IT 137421-73-9 CAPLUS  
 CN Benzenesulfonic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)methyl]amino-, methyl ester (CA INDEX NAME)




- IT 137421-75-3 CAPLUS  
 CN Benzenesulfonic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)methyl]amino-, methyl ester (CA INDEX NAME)




FR 151954-53-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino-, methyl ester (CA INDEX NAME)




FR 151954-53-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino-, methyl ester (CA INDEX NAME)




FR 151954-54-0 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]methylamino-, methyl ester (CA INDEX NAME)




FR 151954-55-1 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]amino-, methyl ester (CA INDEX NAME)




FR 151954-59-5 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino-, 2,5-difluoro-, ethyl ester (CA INDEX NAME)




FR 151954-62-8 CAPLUS  
CN Benzenesacetic acid, 2-chloro- $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino-, ethyl ester (CA INDEX NAME)




FR 151954-61-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino-, 3-methyl-, ethyl ester (CA INDEX NAME)




FR 151954-56-2 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino-, methyl ester (CA INDEX NAME)




FR 151954-57-3 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]propylamino-, methyl ester (CA INDEX NAME)




FR 151954-58-4 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-methylphenyl]-2-propen-1-ylamino-, ethyl ester (CA INDEX NAME)



FR 151954-62-0 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino-, 2,5-difluoro-, ethyl ester (CA INDEX NAME)




FR 151954-63-1 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino-, 3-chloro-, ethyl ester (CA INDEX NAME)




FR 151954-64-2 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino-, 2,5-difluoro-, ethyl ester (CA INDEX NAME)






- IT 141119-32-4P 142219-26-9P 149350-05-4P  
 RI: SYN (Synthesis preparation); PREP (Preparation)  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-[phenylmethyl]ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RI 142219-26-9 CAPLUS  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-[phenylmethyl]ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RI 148550-05-4 CAPLUS  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]-1-[(phenylmethyl)-, (S)- (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER:

DOCUMENT NUMBER:

ORIGINAL REFERENCE NO.:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PRIORITY APPL. INFO.:

OTHER SOURCE(S):

GI:

SUBMIT 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562

NOV94 119:147562


NOV94 119:147562

NOV94 119:147562


NOV94 119:147562

NOV94 119:147562


NOV94 119:147562




- IT 137421-60-4P  
 RI: RCT (Reactant); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-[phenylmethyl]ethyl]-, (S)- (9CI) (CA INDEX NAME)




ON CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITING)




- RI 146555-61-5 CAPLUS  
 CH Benzenamine, 4-[[2-(3-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




- IT 146555-58-0P 146555-59-1P  
 RI: RCT (Reactant); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-[phenylmethyl]ethyl]-, (S)- (9CI) (CA INDEX NAME)



- RI 146555-59-1 CAPLUS  
 CH Benzenamine, 4-[[2-(3-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



- IT 146555-62-4P 146555-63-7P 146555-64-8P  
 RI: RCT (Reactant); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-[phenylmethyl]ethyl]-, (S)- (9CI) (CA INDEX NAME)




AS The title derives. 1 R = Cl-3 ethylthio; R1 = carbonyl, sulfonyl; X = H, halo; and their salts, useful for treatment of hypertension and heart failure, are prepared. A solution of 3.05 g 2-butyl-3H-imidazo[4,5-b]pyridine preparation given in DMF was stirred with NaH and then treated with

1.85 g 4-nitrobenzyl bromide at 0° for 5 h to give 0.78 g 2-butyl-3-[(4-nitrophenyl)methyl]imidazo[4,5-b]pyridine, 1.03 g of which was heated with Fe and AcOH in toluene under reflux for 6 h to give 0.84 g 2-butyl-3-[(4-nitrophenyl)methyl]imidazo[4,5-b]pyridine (II). Then, 3.0 g II was treated with 2.6 g 2-methylbenzothiazole in CH2Cl2 at room temperature overnight to give 2.4 g 1 R = H, R1 = CO2H, X = H, which inhibited Angiotensin II binding in rat adrenal microsome with an IC50 of 0.034 μM.


IT 146555-62-4P 146555-63-7P  
 RI: RCT (Reactant); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)  
 CH 18-Pyrazole-3-carboxylic acid, 2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-2-oxo-1-[phenylmethyl]ethyl]-, (S)- (9CI) (CA INDEX NAME)

RI 146555-62-4 CAPLUS  
 CH Benzenamine, 4-[[2-(3-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)


16 ANWEX 24 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)




RD 146555-63-7 CAPLUS  
CN Benzoic acid, 2-[[[4-[[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RD 146555-64-3 CAPLUS  
CN Benzoic acid, 2-[[[4-[[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RD 146555-63-3 CAPLUS  
CN Benzoic acid, 2-[[[4-[[2-(butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]-3,4-dichloro- (CA INDEX NAME)



RD 146555-66-0 CAPLUS


16 ANWEX 24 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)

RD 146555-70-6 CAPLUS  
CN Benzenesulfonic acid, 2-[[[4-[[2-(ethylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)




OS\_CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


16 ANWEX 24 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM (Continued)




RD 146555-67-1 CAPLUS  
CN Benzenesulfonic acid, 2-[[[4-[[2-(butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RD 146555-68-2 CAPLUS  
CN Benzenesulfonic acid, 2-[[[4-[[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RD 146555-69-3 CAPLUS  
CN Benzenesulfonic acid, 2-[[[4-[[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]carbonyl]- (CA INDEX NAME)





16 ANWEX 23 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STM

1992;46:9865 CAPLUS  
DOCUMENT NUMBER: 117469865  
ORIGINAL REFERENCE NO.: 1174;12394,12394  
TITLE: Preparation of imidazopyrimidinylacetanilide derivatives as angiotensin II antagonists  
INVENTOR(S): Sincar, Ila  
PATENT ASSIGNOR(S): Merck-Lambert Co., USA  
SOURCE: PCT Int. Appl., 64 pp.  
DOCUMENT TYPE: OTHER: P10402  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9206083	A1	19920416	WO 1991-086798	19910919
W1 AU, CA, CN, FI, JP, FR, WO, US				
W1 AU, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
US 5142359	A	19930907	US 1991-757021	19910913
AU 5186259	A	19930428	AU 1991-86590	19910919
PRIORITY APPL. INFO.:			US 1990-590626	A 19900928
			US 1991-757021	A 19910913
			WO 1991-086798	A 19910919

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L505 DISPLAY FORMAT  
OTHER SOURCE(S): MASPAT 117:69865  
CI



AS Title compds. I [R, R1 = C, N; R2 = H, halo, Cl-6 alkyl, alkoxyalkenyl, carboxyalkyl, trihalomethyl, perfluoroethyl, cyano, cyano, alkoxyethyl, hydroxyethyl, CO2R, etc.], R1 is absent when R = R2 = R = 6-membered (substituted) heterocyclic ring when R = C, R, R1 = vinyl, C2-10 alkyl, aryl, heteroaryl, etc., when R = C, R2 = H, Bu.



16 ANMER 25 OF 29 CAPLUS COUNTERFET 2011 ACS ON STM (Continued)  
cycloalkyl, alkyl, propargyl, OMe, OMe, etc.; R3 = C6H4R6; R4 = H.

11-6 alkyl, (substituted) aryl, etc.; when R5 = H; R6 = cyano, CO2R, tetraalkyl, etc.; or R5R6 = CO, CH2R, were prep'd. as angiotensin II antagonists useful as antihypertensives. Thus, 1-phenylalanine was cyclized with Me 2, 5-dimethylpyridine-2-carboxylate to give 2-(methoxycarbonyl)-5-phenylmethyl-1-pyrrol-1-ylmethyl acid. This was coupled with


1-[4-(aminomethyl)methyl]-2-butyl-4-chloro-3H-imidazole-5-methanol (prepn. given) in the presence of 1-hydroxybenzotriazole and DCC to give title compd. (33-1). The latter was effective at 0.22 µM in vitro in inhibiting binding of 3H-angiotensin II to rat liver membranes.

141219-21-4F 141219-24-9F R1 RAC (Biological activity or effector, except address); R2U (biological)

study, unclassified); SPH (Synthetic preparation); THO (Therapeutic use); R2U (Biological study); PREP (Preparation); USES (Uses)


[Preparation of, as angiotensin II antagonist]  
R1 141219-21-4F CAPLUS  
CN 1R-pyrrol-2-carboxylic acid, 1-[2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-oxo-1-phenylmethyl]ethyl-, methyl ester, (S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



141219-26-9 CAPLUS  
CN 1R-pyrrol-2-carboxylic acid, 1-[2-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-3-oxo-1-phenylmethyl]ethyl-, (S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



17 137421-60-4F 137421-61-5F  
R1 SPH (Synthetic preparation); PREP (Preparation)  
[Preparation of, as intermediate for angiotensin II antagonists]

R1 137421-60-4F CAPLUS  
CN 3H-imidazo[4,5-b]pyridine,  
2-ethyl-5,7-dimethyl-3-[[4-(methoxyphenyl)methyl]-  
(CA INDEX NAME)

16 ANMER 26 OF 29 CAPLUS COUNTERFET 2011 ACS ON STM (Continued)  
ACCESSION NUMBER: 199142656 CAPLUS  
DOCUMENT NUMBER: 11742656  
ORIGINAL REFERENCE NO.: 11746034, 4004

TITLE: Preparation of [1-tetracyclopropyl]benzylimidopyridines and related compounds as angiotensin II antagonists

INVENTOR(S): Shimizu, Hiroshi, Takayuki, Saitoh, Yuki, Furuta, Akio, Tanaka, Hiroaki

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SCC(S): Eur. Pat. Appl., N4 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION: 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 480204	A1	19920415	EP 1992-115444	19930904
EP 480204	A2	19930205		
US 5121592	A	19930511	US 1993-748994	19930803
US 518454	A	19930402	US 1993-40454	19930904
AU 650479	A2	19940629		
IT 514346	A	19930506	IT 1993-4363	19930904
CA 510728	A	19920729	CA 1992-7228	19930901
AU 135702	T	19900415	AU 1991-115444	19920504
CA 528123	A1	19920205	CA 1992-0205	19930904
CA 2052125	A1	19920206	CA 1992-2052125	19930904
NO 513710	A2	19920206	NO 1992-376	19930904
RU 5944	A2	19920208	RU 1991-3052	19930904
JP 04288075	A	19921013	JP 1992-27989	19930904
PRIORITY APPL. INFO.			GR 1990-20838	A 19900905
			GR 1990-23467	A 19901019
			GR 1990-28226	A 19901231
			GR 1991-3974	A 19930205
			GR 1991-4954	A 19930403
			GR 1992-7221	A 19930505
			GR 1991-12803	A 19930604

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LISTS DISPLAY FORMAT

OTHER SOURCE(S): MARCH 11735466

GI For diagram(s), see printed CA issue.

A2 Title complete: (i) R3 = H, halo, NO2, alkyl, alkoxy, (acylamino) R2-R4 =

R, halo, NO2, cyano, alkyl, alkoxy, alkylthio, haloalkyl, haloalkyl, hydroxyalkyl, (substituted) haloalkyl, R2R3 = CO2C(CH3)2, R5 = H, protecting


group A = alkylamino, Q = CH, NH, Y = NH, O, S; Z = atoms to complete a

(substituted) benzenoid indolizine, were prepared. Thus, 2-[4-(4-oxo-2-oxo-1-pyrrol-1-ylmethyl)-2-methyl-7-methyl-3H-imidazo[4,5-b]pyridine


was heated with Me3SO in xylene to give title compound (10).

11

16 ANMER 25 OF 29 CAPLUS COUNTERFET 2011 ACS ON STM (Continued)



R1 137421-63-5 CAPLUS  
CN Benzamide, 4-[[2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



OC-CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS

RECORD

REFERENCE COUNT: 2 (3 CITINGS)

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RS

FORMAT


16 ANMER 26 OF 29 CAPLUS COUNTERFET 2011 ACS ON STM (Continued)  
Inhibited angiotensin II in guinea pig ileal strips with IC50 = 1.7

17 142014-19-5F 142014-23-1F 142014-24-2F  
R1 RAC (Biological activity or effector, except address); R2U (biological)


study, unclassified); SPH (Synthetic preparation); THO (Therapeutic use); R2U (Biological study); PREP (Preparation); USES (Uses)

[Preparation of, as angiotensin II antagonist]

R1 142014-19-5F CAPLUS  
CN 3H-imidazo[4,5-b]pyridine,  
2-butyl-7-methyl-3-[[2-nitro-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl]- (CA INDEX NAME)



R1 142014-23-1 CAPLUS  
CN 3H-imidazo[4,5-b]pyridine,  
2-butyl-7-methyl-3-[[2-nitro-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl]-, sodium salt (1:1) (CA INDEX NAME)




R1 142014-24-2 CAPLUS  
CN Acetamide,  
N-[1-[[2-butyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-  
(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, sodium salt (1:1) (CA INDEX NAME)


11




16 ANNEX 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
bipyridin-3-ylmethylphenylamino)- (CA INDEX NAME)




20 151914-17-5 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-2-propen-1-ylamino)- (CA INDEX NAME)



20 151914-18-6 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino)- (CA INDEX NAME)




20 151914-20-0 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl](2-methylpropylamino)- (CA INDEX NAME)




20 151914-22-2 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propylamino)- (CA INDEX NAME)


16 ANNEX 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
ylmethyl]phenyl)-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)




20 137423-63-7 CAPLUS  
CN Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenylmethyl)-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)



20 137423-64-8 CAPLUS  
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-8-methyl)- (CA INDEX NAME)




20 137423-65-9 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino)-, methyl ester (CA INDEX NAME)



20 137423-66-0 CAPLUS


16 ANNEX 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
3H-imidazo[4,5-b]pyridin-3-ylmethylphenylamino)- (CA INDEX NAME)




17 137423-62-4P 137423-63-4P 137423-64-4P  
137423-65-4P 137423-66-4P 137423-67-4P  
137423-68-4P 137423-69-4P 137423-70-4P  
137423-71-4P 137423-72-4P 137423-73-4P  
137423-74-4P 137423-75-4P 137423-76-4P  
137423-77-4P 137423-78-4P 137423-79-4P

20a BAC (Biological activity or effector, except address); BUD (Biological)  
study, unclassified); OH (Synthetic preparation); TH (Therapeutic use);  
R100 (Biological study); PEP (Preparation); HSE (Hose)  
[preparation of, as intermediate for amphetamine 11 antagonist]

20 137423-60-4 CAPLUS  
CN 3H-imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[(4-nitrophenyl)methyl]-  
(CA INDEX NAME)




20 137423-61-5 CAPLUS  
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




20 137423-62-6 CAPLUS  
CN Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenylmethyl)-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)


16 ANNEX 27 OF 29 CAPLUS COPYRIGHT 2011 ACS on STM (Continued)  
CN Carbanic acid, ethyl[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)




20 137423-67-1 CAPLUS  
CN Benzenamine, 8-ethyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)



20 137423-68-2 CAPLUS  
CN Benzenesacetic acid,  $\omega$ -[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methylamino)-, methyl ester (CA INDEX NAME)




20 137423-69-3 CAPLUS  
CN Carbanic acid, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenylmethyl)-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)




137421-70-6 CAPLUS

137421-70-6 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)




137421-71-7 CAPLUS

137421-71-7 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]propyl]- (CA INDEX NAME)




137421-72-8 CAPLUS

137421-72-8 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




137421-73-9 CAPLUS




137421-71-3 CAPLUS

137421-71-3 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl]- (CA INDEX NAME)



137445-34-8 CAPLUS

137445-34-8 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]methyl]- (CA INDEX NAME)



ON-CITING REF COUNT: 9

THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD


(9 CITINGS)

REFERENCE COUNT: 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD


FORMAT

137421-74-0 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)




137421-74-0 CAPLUS

137421-74-0 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)



137421-75-1 CAPLUS

137421-75-1 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)



137421-76-2 CAPLUS

137421-76-2 CAPLUS  
Benzenesulfonamide, 4-[[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, methyl ester (CA INDEX NAME)

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

137445-34-8 CAPLUS

16 APPENDIX 29 OF 29 CAPLUS COPYRIGHT 2011 ACS ON STN

ACCESSION NUMBER: 1971:428258 CAPLUS  
 DOCUMENT NUMBER: 75:28259  
 ORIGINAL REFERENCE NO.: 75:4455a,4454a  
 TITLE: Photographic products comprising alkali-hydrolyzable  
 anti-fogging precursors  
 INVENTOR(S): Bloom, Stanley N.; Rogers, Howard Gardner  
 PATENT ASSIGNER(S): Polaroid Corp.  
 SOURCE: U.S., 13 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. REM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 353549	A	1971:04:20	US 1968-754028	1968:09:03
PRIORITY APPL. INFO.			US 1968-754038	A 1968:09:03


GI For diamane(s), see printed CA Index.

AB Inactivated anti-fogging for incorporation in a photo. system such as a diffusion transfer film have the general formula I, where Y is CH or N, X is H or CH and S is H or alkyl of less than C<sub>6</sub>, and Z is an alkali-hydrolyzable deactivating group. Z is removed by hydrolysis on contact with the alkaline processing composition of a rate dependent on temperature and independent of exposure and development. S is comprised of acyl or β-acylalkyl groups.

IT 33007-71-5  
 ELI CHEM (U.S.A.)  
 (photographic emulsions fog inhibitor precursor)

NI 33007-71-5 CAPLUS

CH 1-decyldecane-11-one,  
 N-[4-[4-(4-oxo-5-oxo-1,2,3,4-tetrahydro-4,5-bipyridin-3-yl)carbonyl]phenyl]- (CA INDEX NAME)



OR-CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS  
 RECORD (3 CITING)

=>

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

200.40

424.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-25.23

-25.23

STN INTERNATIONAL LOGOFF AT 10:31:35 ON 11 FEB 2011